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ABSTRACT 
IDENTIFICATION OF TISSUE AND CIRCULATING BIOMARKERS FOR 
PREMALIGNANT AND MALIGNANT LESIONS 
Shu-Hong Lin, B.V.M, M.S. 
Advisory Professor: Xifeng Wu, M.D., Ph.D.  
Recent advancement in technologies including next-generation sequencing and 
production-scale throughput qPCR have revolutionized the identification of 
biomarkers in the epidemiology field. In response to the vast amount of data 
generated from high-throughput technologies, novel inventions in the computer 
sciences fields have been applied to analyze these data. The current study 
demonstrates the application of such technologies in a variety of scenarios.  
I first described how targeted and whole-exome sequencing were used to 
identify somatic mutations which marked the differences between colorectal 
adenomas and adenocarcinomas. A statistical test based on the unique clustering 
pattern of tumor suppressor genes and oncogenes was employed to locate driver 
mutations. Random forest algorithm was performed to find somatic mutations which 
best classify samples into adenoma and adenocarcinoma.  20 important mutated genes 
(TP53, KRAS, APC, PIK3CA, SMAD4, FBXW7, CTNNB1, SYNE1, CDC27, CSMD1, 
NRAS, RYR3, NALCN, LRP1B, FAT4, ATM, TMPRSS13, SOX9, CSMD3, MED12) 
which constantly served to separate adenomas from adenocarcinomas  were 
discovered.  
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The Second project focused on exploring differentially expressed genes (DEG) 
and pathways enriched with such genes in colorectal adenomas and adenocarcinoma s. 
Fold changes of paired premalignant/malignant lesions compared to normal adjacent 
tissues from the same patient were analyzed.  And the ratio of 20-gene panel found in 
the first project were also found to differ between colorectal adenomas and cancers.  
The last project in the dissertation demonstrated the potential for microRNA 
(miR) in the serum to be used as a non-invasive prognostic factor for non-muscle 
invasive bladder cancers (NMIBC). With the help from a vast amount of miR 
profiles, we were able to identify two panels in overall population (miR-16/miR-378 + 
miR-24/miR-331-3p for recurrence and  miR-16/miR-21 + miR-24/miR-375 for progression) 
and two panels in BCG-treated population (miR-16/miR-378 + miR-24/miR-331-3p for 
recurrence and miR-16/miR-21 + miR-24/miR-375 for progression). 
Taken together, these projects showcased the discovery of  tissue and 
circulating biomarkers with cutting-edge technologies. These biomarkers could lead 
to more informed distribution of limited medical resources for monit oring clinical 
outcomes as well as the origin for future studies on deciphering the intricate 
mechanisms underlying tumorigenesis, host response and patient survival .  
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1. Introduction 
1.1. Epidemiology and etiology of colorectal cancer and adenoma 
With estimates of 75,610 and 64,640 new cases in males and females, colorectal cancer (CRC) 
remained the 3rd most incident cancer when both sexes combined in the U.S. in 2018. In terms of 
mortality, colon cancer is the 3rd most deadly cancer with 27,390 and 23,240 deaths in male and female 
which only lung and prostate/breast cancers could surpass (Siegel et al., 2018). Most colorectal cancers 
are sporadic, although the contribution of genetic background could be as high as 23.5% in certain ethnic 
groups if we assume all colorectal cancer patients as hereditary whenever they meet one or more 
situations listed in the Revised Bethesda Guidelines (Piñol et al., 2005). Risk factors for CRC includes 
inflammatory bowel disease, sex, family history, body mass index, exercise, smoking, alcohol 
consumption, race, diabetes, red meat intake, fruit and vegetables consumption (Fedirko et al., 2011; 
Guraya, 2015, p. 2; Johnson et al., 2013; Nguyen et al., 2009).  
Adenomas (AD) are regarded as the precursor of CRC, and the prevalence of AD increases as people 
age. An epidemiological necropsy reported 1.72 to 3.59% in people younger than 50 years old, and 10.10 
to 12.06 in those older than 50 (Pendergrass et al., 2008). Similar to CRC, males are more likely to have 
AD compared to females. And the risk factors for AD are similar to CRC with BMI , smoking, alcohol, 
age, sex, exercise, family history, diabetes, red meat, fruit (Ashktorab et al., 2014; Aune et al., 2013; Ben 
et al., 2015; Cao et al., 2015; Onega et al., 2010; Terry et al., 2002; Vu et al., 2014; Yu et al., 2016).  
1.2. Model of CRC tumorigenesis and subtypes 
The development of CRC is pictured as a series of assaults which disrupts the physiology of 
colorectal epithelia and eventually leave permanent changes to these cells genetically or epigenetically. 
A classical genetic model was proposed by Volgestein et al. and expanded over the years where APC 
mutation mark the beginning of hyperproliferative epithelia, COX-2 overexpression and other events 
drive these lesion into adenomas, and KRAS and p53 mutations transform the adenomas into carcinomas 
(Fearon and Vogelstein, 1990). Despite the elegance of this model, it has turned out to represent only a 
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fraction of the whole picture. Two studies each had around 100 patients tried to quantify the percentage 
of CRC which carried the APC-KRAS-TP53 mutation repertoire, and only 6.6% and 23% did (Frattini et 
al., 2004; Smith et al., 2002). Later studies clearly delineated other pathways of CRC tumorigenesis, and 
also showed that the adenoma referred in the aforementioned model is not the only type of premalignant 
lesion which eventually becomes CRC.  
Years of intensive research laid out three molecular mechanisms which contribute alone or in concert 
towards CRC tumorigenesis: chromosomal instability (CIN), microsatellite instability (MSI), and CpG 
island methylator phenotype (CIMP) (Issa, 2008; Tariq and Ghias, 2016). The cancers driven by CIN 
pathway ultimately present with loss of entire genes (loss of heterozygosity, LOH) and abnormal number 
of chromosomes (aneuploidy). The exact genes involved in CIN pathway have suggested but not reached 
a conclusion, and candidates include but not limiting to APC, TP53 and FBXW7 (Fodde et al., 2001; 
Gualberto et al., 1998; Rajagopalan et al., 2002). Microsatellite refers to short repeated sequence in the 
genome, and these sequence are susceptible to defect in DNA repair system. Therefore, CRC with 
changes in microsatellite is referred to as MSI driven. Most sporadic MSI CRC have been found to lose 
MLH1 or MLH2 expression (Lanza et al., 2002), and hereditary CRC with MSI have been shown to be 
due to mutations in MLH1, MSH2, MSH6 and PMS2 (de la Chapelle, 2004). Finally, CIMP is 
characterized by methylation of tumor suppressor gene promotors, and CIMP high has been positively 
associated with high BRAF and TGFBR2 mutations and negatively associated with TP53, CDKN1A and 
COX-2 aberrations (al, n.d., p. 21; Ogino et al., 2006; Samowitz et al., 2005). An effort was made to 
classify CRC into five categories based these three features: 1) CIMP-high, no CIN, MSI-high, BRAF 
mutation and MLH methylation, accounts for 12% of CRC. 2) CIMP-high, no CIN, microsatellite stable 
(MSS) or MSI-low, BRAF mutation and partial MLH1 methylation, 8% of CRC. 3) CIMP-low, CIN, 
MSS or MSI-low, KRAS mutation, MGMT methylation, 20% of CRC. 4) No CIMP, CIN, MSS, 57% of 
CRC. 5) no CIMP, no CIN, MSI-high, no BRAF mutation, 3% of CRC. Among the five categories, 
category 5 is observed in Lynch syndrome, conventional adenoma (CNAD) possibly contributed to 3 and 
4 while sessile serrated adenoma (SSA) contributed to 1, 2 and 3 (Jass, 2007). 
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1.3. Development of tests for CRC based on molecular markers 
Here I present a case to demonstrate that the characterization of genetic and epigenetic aberrations in 
CRC can eventually lead to the development of a stool DNA test for early detection. The first stool DNA 
test proposed was based on KRAS mutations in 1992 by Sidransky et al. (Sidransky et al., 1992). 
Scientists soon realized that mutation from a single gene does not cover the heterogeneity of CRC, and 
the sensitivity fluctuated between 57 to 100%. Thus, a multi-target test containing KRAS, APC, TP53, a 
microsatellite marker, and a long DNA to test for apoptosis events was developed. This panel achieved 
91% sensitivity in a cohort of 22 CRC, 11 AD and 28 normal tissue from health individuals (Ahlquist et 
al., 2000). The test was compared to the most popular CRC screening, fecal occult blood test (FOBT), 
and seemingly outperformed FOBT in terms of sensitivity while maintaining comparable specificity in a 
5,486 subject study (Imperiale et al., 2004). Soon, a methylation marker was added to the panel in 2008 
for added performance (Ahlquist et al., 2008). After that, another panel which measures BMP3 and 
NDRG4 promoter methylation, KRAS, and human hemoglobin was tested in 9,989 patients yielding 
92.3% sensitivity and 86.6% specificity (Imperiale et al., 2014). The whole process demonstrated how 
such tests could advance as our knowledge of CRC improved. The same concept could be applied to the 
study of premalignant lesions. The understanding of molecular subtypes of AD will inform the design of 
interventions which will have potential to prevent CRC from developing. Chapter 2 and 3 of this 
dissertation is dedicated to building the foundation of molecular differences between various subtypes 
and stages of AD. 
1.4. Epidemiology, etiology, treatment and outcome of bladder cancer 
Bladder cancer (BC) is the 4th most common newly diagnosed cancer in men with 49,690 estimated 
new cases in 2018. The incidence in women is much lower at 18,810. Death from BC is predicted to be 
12,520 in men and 4,720 in women in 2018. Risk factors for BC include male, smoking, race, age, 
ethnicity, exposure to arsenic, aromatic amines, 4,4'-methylenebis(2-chloroaniline), pioglitazone 
(treatment for diabetes), Cytoxan (chemotherapy), radiation therapy of the pelvis, low water intake,  
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urinary and kidney stones, urinary infections, Schistosomiasis, and family history (Burger et al., 2013; 
Fajkovic et al., 2011; Letašiová et al., 2012; May et al., 2012; Yee et al., 2011).  
BC is usually classified into non-muscle-invasive (NMIBC) and muscle-invasive (MIBC). NMIBC 
includes BC in Ta, Tis and T1, and 70% of patients were diagnosed with NMIBC (Kaufman et al., 
2009). Among these stages, Ta means non-invasive papillary carcinoma; Tis refers to carcinoma in situ; 
T1 means the tumor has invaded into lamina propria (Edge and American Joint Committee on Cancer, 
2010). Starting at T2 onward, the tumor has invaded into the muscle layer and beyond, thus referred to as 
MIBC. Five year mortality of NMIBC was about 10% while patients who progressed to MIBC, despite 
radical treatments like cystectomy was performed, had a five year mortality rate at ~40% depending on 
stage (Funt and Rosenberg, 2017). 
Although the relative five-year mortality rate of 22.7% for all stages combined is not especially high 
compared to other cancers, BC is known for high recurrence rate. The five year recurrence rate of 
NMIBC is between 31 to 78%, and progression rate is between 0.8-45% depending on stage (Rhijn et al., 
2009). The high recurrence rate and the undeniable risk of progression created the need for constant 
surveillance and frequent treatments. A report published in 2014 showed that BC cost 4 billion USD per 
year and had the highest per patient cost (Mossanen and Gore, 2014). Such a substantial medical expense 
and use of resources necessitates better strategies in management of BC. 
1.5. Treatment of NMIBC by Bacillus-Calmette-Guérin 
Current standard treatments of NMIBC are often comprised of an initial removal of tumor via 
transurethral resection (TUR) followed by intravesical induction Bacillus-Calmette-Guérin (iBCG) 
weekly for 6 installation and 1-3 years of maintenance BCG (mBCG) treatment (Oddens et al., 2013). 
BCG is a attenuated strain of animal bacilli developed by Albert Calmette and Camille Guerin for the 
vaccination against tuberculosis (Calmette, 1931). In 1935, Holmgren published the first report about 
using BCG as a cancer vaccine (Alexandroff et al., 1999), but the concept was not well accepted until  
Mathé et al. demonstrated their results on treating lymphoblastic leukemia (Mathé et al., 1969). Yet the 
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development of chemotherapy and radiotherapy along with some failure in reproducing similar benefit 
made BCG immunotherapy unpopular. The first success of treating BC with BCG was reported by 
Morales et al. in 1976 (Morales et al., 1976), but the extensive acceptance of BCG as BC treatment did 
not occur until it was demonstrated to reduce BC recurrence significantly in a randomized prospective 
study in 1980 (Lamm et al., 1980). 
After intravesical administration of BCG, normal and cancerous urothelial cells engulfed BCG by 
endocytosis. The anticancer activity of BCG infection could be categorized in two aspects. First, BCG-
infected cells expressed the costimulatory molecule, intracellular adhesion molecule (ICAM-1), which 
facilitated interaction between cancer cell, T cell and neutrophils. Combined with upregulation of MHC 
II, cancer cells might function as antigen-presenting cells and promote T cell activation (Lattime et al., 
1992). Infected cancer cell could also attracted immune cells via producing chemokines like IL-6, IL-8, 
IL-12, GM-CSF, IFN-α and TNF-α (Alexandroff et al., 1999; Alexandroff and Patel, 2010). Besides, 
BCG had been found to induce necrosis of bladder cancer cells as well (See et al., 2009).  
Multiple meta-analyses have pointed out that, compared to chemotherapy with mitomycin C 
(MMC), BCG offers benefit for high risk BC in terms of recurrence, but survival and progression 
remained similar between the two treatments. Despite the benefit in diminishing recurrence, BCG is not 
without caveats. The major downside of BCG treatment is higher toxicity reported in all studies (Shelley 
et al., 2001). After summarizing available meta-analysis on toxicity, Böhle et al. concluded that BCG 
treatment resulted in a higher rate of cystitis (odds ratio 1.8, 95% CI: 1.48-2.23), but MMC seemed to 
have higher rate of allergy and skin reactions (Böhle et al., 2003). In general, the side effect of BCG 
treatment is more severe than that of MMC. Therefore, a better risk stratification strategy is desired to 
identify patients who are suitable for BCG treatment. 
1.6. microRNA and cancers 
 microRNAs are small non-coding RNA molecules about 22 nucleotide in length. In 1993, Lee et 
al. reported a gene, lin-4, that controlled the development of C. elegans, and expression of this gene 
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inhibited a protein called lin-14. Interestingly, the lin-4 gene had no start or stop codon, and introduction 
of mutations did not seem to change its function. The authors determined that one of the transcripts of 
lin-4 was only 22 nucleotide long, and its sequence is complementary to a region on the 3’UTR of lin-14 
mRNA (Lee et al., 1993). This novel regulatory mechanism of protein expression revolutionized biology 
and started a whole new research field on the biological significant of microRNA. Later studies 
elucidated the biogenesis of microRNA, the mechanism behind gene downregulation, and its 
multifaceted roles in human physiology. 
 The first report linking microRNA and human cancer was published by Calin et al. in 2002. The 
authors discovered that genes which encoded microRNA-15 (miR-15) and miR-16 resided in a 
frequently deleted region of B cell chronic lymphocytic leukemias (Calin et al., 2002). Later publications 
from the same group found that miR-15 and miR-16 inhibit leukemia cell growth via down-regulating 
Bcl-2 (Cimmino et al., 2005). In a 2016 review, Peng and Croce summarized known roles of 
dysregulated miRNA in cancers: 1) promote proliferation signaling and demote growth suppression, 2) 
evasion of apoptosis, 3) facilitate invasion and metastasis and 4) strengthen angiogenesis. 
1.7. Circulating microRNA as a biomarker for cancer 
 The advantage for circulating biomarkers lies mainly in its non-invasive nature. Many 
circulating markers have been used in the clinic to aid diagnosis such as aspartate transaminase (AST),  
alanine transaminase (ALT), and gamma-glutamyl transferase (GGT) for liver function; creatinine and 
blood urea nitrogen for kidney function; amylase and lipase for pancreatic function. Because of the 
success of these biomarkers, development of novel biomarkers holds promise. 
microRNAs have advantages which make them suitable as a biomarker. First, microRNAs are 
relatively stable compared to protein or mRNA. Studies have shown that microRNAs were relatively 
stable despite exposure to repeated freeze-thaw cycles, RNase, and inclement pH (Chen et al., 2008; 
Gilad et al., 2008; Mitchell et al., 2008). Second, the isolation and detection of microRNA is based on 
qPCR which has been widely used in the biomedical field. Third, prediction algorithms for microRNA 
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targets, along with studies on the role of microRNAs in cancer cells, provide a certain level of biological 
plausibility. The association between circulating microRNA and cancers was first featured in a study by 
Lawrie et al. who discovered that serum level of cancer-associated microRNAs were higher in patients 
with diffuse large B-cell lymphoma (Lawrie et al., 2008). In the following years, a significant amount of 
studies expanded such association to various conditions including cancer detection, recurrence, and 
progression. In a review by Singh et al. in 2016, microRNAs have been reported to act as biomarkers in 
breast, cervical, colorectal, gastric, hepatocellular, esophageal, oral, pancreatic, rectal, and thyroid 
cancers (Singh et al., 2016). 
Despite the favorable characteristics of microRNA and a huge amount of publications on 
success, circulating microRNA faces certain problems including contamination from coagulation, low 
reproducibility among studies, untraceable origin, and unknown confounders (Singh et al., 2016). In 
Chapter 4 of this dissertation, we tried to minimize the impact of these pitfalls via sample quality control, 
two-stage study design, and controlling for possible confounders statistically. 
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2. The somatic mutation landscape of premalignant colorectal adenoma 
This chapter is based upon Lin, S.-H., Raju, G.S., Huff, C., Ye, Y., Gu, J., Chen, J.-S., Hildebrandt, M.A.T., Liang, 
H., Menter, D.G., Morris, J., Hawk, E., Stroehlein, J.R., Futreal, A., Kopetz, S., Mishra, L., Wu, X., 2017. The 
somatic mutation landscape of premalignant colorectal adenoma. Gut. https://doi.org/10.1136/gutjnl-2016-313573. 
The publication was under a CC-BY-NC license which grants authors the right for non-commercial use. 
2.1. Introduction 
Cancer is a progressive disease that results from the accumulation of genetic and molecular 
changes over many years. Many cancers were detected and treated at an advanced stage using 
chemotherapy and radiation with disappointing results. In order to avoid such outcome, the better 
strategy is to detect cancer as it develops, at its earliest stages, because it allows for a preventive 
intervention to stop or even reverse the process of tumorigenesis. Most epithelial cancers are preceded by 
premalignant lesions. Therefore, detection of premalignant lesion has become one of the most popular 
preventive measures against tumor progression. This paradigm is especially true for colorectal cancer. 
Up until now, the gold standard diagnosis and preventive measure for colorectal cancer has been 
colonoscopy. However, colonoscopy is not only a financial burden but also a source of complications 
and discomfort to patients. Previous literature has suggested that about 25% asymptotic and average-risk 
patients develop colon adenomas (Neugut et al., 1997), a precursor to colon cancer. But the annual rate 
of transition to colorectal cancer (CRC) was between 2.5-5.6% even for advanced adenomas(Brenner et 
al., 2007). On the other hand, the annual health care expenditure for colonoscopy has reached $10 
billion. An analysis has shown that the largest cost to the health care system generated by colonoscopy 
relates to future surveillance when adenomas are found at baseline colonoscopy. And current guidelines 
for surveillance colonoscopy are based on empirically generated descriptors which are imprecise(Zhu et 
al., 2014). Thus, an improved risk stratification based on molecular signature of the adenoma is highly 
desirable. For individuals with low risk, a less frequent screening strategy could be applied to reduce the 
economic burden. Previously, large-scale sequencing projects have advanced the understanding of CRC 
pathology (Cancer Genome Atlas Network, 2012). An increasing body of evidence has indicated that 
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certain driver mutations were more prevalent in premalignant lesions compared to malignant lesions 
(Kato et al., 2016). To establish colorectal adenoma genome atlas, identify molecular signatures,  and 
create prediction model for its malignant progression,  we carried out whole exome sequencing (WES), 
targeted sequencing, and compared sequencing data from TCGA CRC tissues(Cancer Genome Atlas 
Network, 2012).  We believe that investigation of somatic mutations in premalignant lesions will provide 
deeper understanding of tumorigenic process of CRC and reveal potential targets for surveillance and 
prevention. 
 
2.2 Material and Methods 
2.2.1 Study population 
Study Participants were recruited from The University of Texas MD Anderson Cancer Center 
between 2010 and 2014 during their routine colonoscopy as part of the Premalignant Genome Atlas 
project. A written informed consent was obtained prior to participation for each participant. There were 
no age, gender, and ethnicity restrictions and those with a diagnosis of Lynch Syndrome were excluded. 
After consenting, each participant was asked to provide blood samples and tissue samples including 
abnormal adenoma/polyps and a normal tissue.  When a lesion/polyps was removed, a portion of it 
would be flash frozen and hand delivered to laboratory for storage for research purpose. The samples 
were labeled with a unique study identification number. Epidemiological data was collected from a 
standard questionnaire through in-person interview by trained MD Anderson staff interviewers and 
clinical and pathological data were abstracted via medical chart review to confirm the diagnosis. 
Adenomas were considered advanced if 1) its diameter was larger than 1cm 2) high-grade dysplasia was 
reported or 3) it has a significant villous component. The study was approved by the Institutional Review 
Board of MD Anderson Cancer Center. 
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2.2.2 DNA isolation and storage 
DNA was extracted from paired blood and adenoma tissue by DNeasy Blood & Tissue Kit 
(QIAGEN, Valencia, CA) according to manufacturer’s instructions. Quality control and concentrations 
were determined by NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE). DNA 
samples were stored at -80oC until used. Infinium CoreExome-24 BeadChip (Illumina, San Diego, CA) 
was employed for QC and confirmation of sample identity. 
 
2.2.3 Custom capture panel design 
Through mining existing databases and a literature review, we designed a custom capture panel 
from four sources detailed below. We first applied MutSig v2.0 or MutSigCV v0.9 (Lawrence et al., 
2013) to identify significantly mutated genes (SMGs) in COAD (Colon Adenocarcinoma) and 
COADREAD (Colorectal Adenocarcinoma) with p<0.05 and population frequency>0.01 using TCGA 
results from Broad GDAC Firehose pipeline (Broad Institute TCGA Genome Data Analysis Center, 
2013). Secondly, we queried driver genes reported previously (Vogelstein et al., 2013) in COSMIC 
database (Forbes et al., 2011) and selected those genes with a population frequency >0.01 in large 
intestine tissues . Thirdly, regions with recurrent copy number variation (CNV) determined by GISTIC2 
(Mermel et al., 2011, p. 2) were covered by manually selected genes to reach at least one gene per 10 
Mbp. Finally, we conducted a comprehensive literature search to identify genes reported to impact 
colorectal cancer. The union of these four sources was 767 genes, and the coordinates of these genes 
were obtained from the UCSC Genome Browser. Design of the capture probes based on the candidate 
genes was carried out by NimbleDesign (Roche, Pleasanton, CA). The final capture probes covered 
99.4% of target bases and the capture target was ~3.6Mbp. 
 
2.2.4 Library preparation, exome capture and sequencing 
Library construction and exome capture was performed in Human Genome Sequencing Center 
(HGSC) at Baylor College of Medicine (BCM) as previously described (Cancer Genome Atlas Network, 
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2012). A complete library construction and exome capture protocol is available on the website of HGSC 
(https://www.hgsc.bcm.edu/sites/default/files/documents/Protocol-
Illumina_Whole_Exome_Sequencing_Library_Preparation-KAPA_Version_BCM-HGSC_RD_03-20-
2014.pdf). In brief, 500 ng of genomic DNA was sheared into fragments with average size of 200-300 bp 
using Covaris S2 System (Covaris, Woburn, MA). Fragmented DNA was subjected to end repair by 
NEBNext End-Repair Module (NEB, Ipswich, MA), 3’-adenylation by NEBNext dA-Tailing Module, 
ligation of Illumina adaptors by NEB Quick Ligase Enzyme and purification by SPRI AMPure XP beads 
(Beckman Coulter, Brea, CA) according to manufacturer’s instructions. Ligation-mediated PCR was 
performed with processed fragments as template using KAPA HiFi HotStart ReadyMix (Kapa 
Biosystems, Wilmington, MA) for 6 cycles. After amplification, SPRI AMPure XP beads were applied 
to purify PCR products. Quality of pre-capture library was then determined by Agilent Bioanalyzer 2100 
DNA 7500 Chip (Agilent, Santa Clara, CA). 
Three μg of pre-capture library was mixed with hybridization buffer, Cot-1 DNA and 
Hybridization Enhancing Oligos (HEO). After denaturing the mixture for 10 minutes at 95°C, SeqCap 
EZ HGSC VCRome capture probes (Roche, Pleasanton, CA) were added which targeted about 37 Mbp 
covering 23585 genes and 189028 exons or aforementioned custom capture probes. Samples were 
incubated at 47°C for 64-72 hours. Streptavidin Dynabeads (Invitrogen, Waltham, MA) were preheated 
at 47°C for 5 minutes and transferred to hybridization reactions. After 45 minutes, beads were washed 
and bound DNA was eluted. The post-capture libraries were amplified with KAPA HiFi HotStart 
ReadyMix for 10-12 cycles. And PCR products were cleaned with SPRI AMPure XP and eluted in 
nuclease-free water.  Every four whole exome or thirty custom capture libraries were pooled and 
sequenced in a single lane of Illumina HiSeq2000 with 2x100 bp paired-end reads.  
 
2.2.5 Pipeline for mapping, somatic mutation calling and annotation 
In order to compare and contrast premalignant (adenoma) and CRC somatic mutation profiles, 
we downloaded TCGA DNA sequencing data for primary CRC tissues (N=460) and corresponding 
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blood samples from the Cancer Genomics Hub (Wilks et al., 2014), dbGaP Study Accession: 
phs000178.v9.p8. The downloaded aligned BAM files were converted to FASTQ files using the 
SamToFastq functionality of Picard Tools V1.118 (http://broadinstitute.github.io/picard). The FASTQ 
files generated from the adenoma and CRC patients were processed by an in-house analysis pipeline 
developed for the sequencing data. FASTQ files were mapped to the human reference genome HG19 
using Burrows-Wheeler Aligner (BWA) V0.7.10 (Li and Durbin, 2009) to generate SAM files. And 
multiple scripts in Picard Tools were employed to fix mate pairs, compress, index, and sort SAM files to 
BAM files. After that, local realignment around known indels identified in dbSNPv137 and the 
1000Genomes Project were performed by Indel Realigner (GATK v.3.3-0) (Van der Auwera et al., 
2013). Duplicates in the realigned BAM were removed by Picard Tools and the base quality was 
recalibrated by GATK Base Recalibrator to generate analysis-ready reads. Somatic variant calls were 
carried out by MuTect V1.1.7(Cibulskis et al., 2013) and VarScan V2.3.7 (Koboldt et al., 2012, p. 2). 
MuTect was run with default parameters while VarScan was run with 3X minimum coverage, minimum 
mean base quality 15, minimum variant allele frequency 0.05 and somatic p-value < 0.05. We pooled the 
variant calls from both callers and applied a universal filter of excluding variants with less than 2 copies 
of reads supporting the alternative base on single nucleotide variants(SNV). Indels were called by 
Varscan with the same parameters used in SNV but were filtered by: (i) total tumor reads > 15; (ii) total 
normal reads > 6; (iii) total number of reads supporting a call > 4; (iv) variant allele frequency (VAF) in 
tumor >5%; (v) VAF in normal <1%. Output from variant callers were converted to VCF format and 
annotated by the variant annotation tool (VAT) in the VAAST2 package (Hu et al., 2013).  
 
2.2.6 Mutation preprocessing, subsetting, prioritization and test for significance 
Annotated mutations were converted to Mutation Annotation Format (MAF) v2.4.1 according to 
NCI specification 
(https://wiki.nci.nih.gov/display/TCGA/Mutation+Annotation+Format+(MAF)+Specification). 
Mutations from TCGA CRC patients marked as “do not use” (DNU) in TCGA annotation manager were 
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removed. Hypermutaters were identified by combining MutL Homolog 1 (MLH1) expression and 
microsatellite stability status. Z scores for MLH1 expression measured by RNAseqV2 and microsatellite 
stability information were downloaded from cbioportal (Gao et al., 2013) via cgdsr package in R 
(Jacobsen, 2015). MLH1 expression Z scores larger than 1.96 corresponding to p value < 0.05 were 
defined as MLH1 dysregulation and median raw expression were employed to further separate 
dysregulation into up-regulation and down-regulation. As for MSI status, both MSI-H and MSI-L were 
defined as MSI. When a patient had more than one mutation of the same gene, the most severe 
consequence was chosen to represent the underlying mutation status of the gene. The order of mutation 
consequences from the most to the least severe was as follows: nonsense, splice site, missense, nonstop, 
silent, untranslated regions (UTR), intronic, and non-coding RNA or unannotated genes . Non-silent 
mutations in our analysis included nonsense, splice site, missense and nonstop mutations. Frequency of 
gene mutations was calculated from MAF files, and previously defined false positive genes (Fuentes 
Fajardo et al., 2012) were removed. In order to identify potential driver genes, we used SomInaClust 
(Van den Eynden et al., 2015).  
 
2.2.7 Identification of mutation signature for adenoma and CRC 
The Student’s t-test was used to compare the difference between adenoma and CRC mutation 
rates. Fisher exact test was employed to determine the difference in mutation frequency among different 
pathological and clinical features. Classification and Regression Tree (CART) analysis (Therneau et al., 
2015) was performed to discover differently mutated genes between sessile serrated adenoma (SSA) and 
tubular villous or conventional adenoma (CA) samples. Supervised learning by random forest and 
permutation tests for variable importance were performed using the randomforest (Cutler and Wiener, 
2015) and rfPermute (Archer, 2016) packages on the pooled dataset containing both adenoma and TCGA 
CRC datasets. Permutation of the random forest class labels were performed for one thousand iterations 
to provide a better estimate of variable importance. A reduced model was constructed on important 
variables identified in random forest with permuted p value < 0.05. For pooled analysis among CRC and 
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adenoma, we further filtered the mutations by VCROME (Roche, Pleasanton, CA) and custom panel 
probes to ensure similar quality of variants.   
 
2.3 Results 
2.3.1 Patient characteristics and sequencing metrics 
This study included a total of 149 patients diagnosed with histologically confirmed adenoma, of 
which whole-exome sequencing (WES) was performed on 49 and targeted sequencing was performed on 
100.  Among them, 35 were advanced lesions, 114 were non-advanced lesions, 14 were SSA, and 135 
were conventional adenomas (CNAD). It is worth noting that pathologists further divided CA into 
tubular, tubulovillous and villous adenomas based on the relative composition of tubular and villous 
component. Adenomas with less than 25% villous structure were referred to as tubular adenoma (TA), 
those with more than 75% villous structure were termed villous adenoma (VA), and those in between 
were named tubulovillous adenoma (TVA). Since the three classification described mixtures of 
continuous gradient rather than discreet categories, we grouped them in our analysis as suggested in 
previous studies (Fleming et al., 2012). Advanced adenoma were adenomas which meet one or more of 
the three following criteria: diameter larger than 1 cm, high grade dysplasia, TVA or VA (Brenner et al., 
2007). There were 43.6% females with a mean age of 59 years. This study also included somatic 
mutation data from TCGA WES data on CRC adenocarcinoma patients for comparison.  We downloaded 
WES data of 460 paired tumor tissue and blood data including 330 colon cancers and 130 rectal cancers 
from Cancer Genomics Hub(Wilks et al., 2014).  Among the 460 pairs of WES data, 378 passed quality 
control including 274 colon cancers and 104 rectal cancers. The stage distribution were 19.8% stage I, 
39.0% stage II, 27.9% stage III, and 13.3 stage IV.  Patient characteristics of two cohorts are detailed in 
Table 2-1 and Table 2-2.   
For the WES in adenoma tissues, 72.27% to 78.13% of reads were mapped to VCRome targets, 
and the median coverage was between 84 and 160 X. While the adenoma samples had an average non-
silent somatic mutation rate of 1.6 per million base pair (mbp), the average rate in the TCGA CRC 
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dataset was significantly higher (10.6/mbp, p = 7.47x10-15). Hypermutaters accounted for a substantial 
proportion of the TCGA CRC cohort which might have biased the average mutation rate. In order to 
identify non-hypermutaters, MLH1 expression and MSI status for CRC samples were obtained for CRC 
samples from TCGA data portal. As shown in Figure 2-1, MLH1 downregulation and MSI-H calls were 
highly clustered in cases with a high mutation rate. Based on mutation rate, MLH1, and MSI status, we 
referred the 66 (17.5%) cases with highest non-silent mutation rates as hypermutaters resulted in a cut-
off rate of non-silent mutation of 11.6/mbp. Limiting the samples to 312 (82.5%) non-hypermutaters 
brought down the rate to 4.6/mbp, yet the distinction between CRC and adenoma patients was even more 
significant (p < 2.2x10-16). As for the CNAD and SSA, no significant difference in somatic mutation rate 
was observed (1.5 and 1.7/mbp, respectively. p = 0.470). And there was no difference in non- advanced 
and advanced adenomas (1.6 and 2.0 /mbp, respectively, p = 0.304). For the following sections, we will 
focus on non-silent somatic mutations with mutation patterns fitting oncogene (OG) and tumor 
suppressor genes (TSG) determined by SomInaClust (Van den Eynden et al., 2015). 
 
2.3.2 Discovery of potential somatic driver mutations in CNAD and SSA using WES 
For CNAD, four genes (CTNNB1, KRTAP4-5, GOLGA8B and TMPRSS13) were found to have 
OG pattern, and APC was the only gene fitting TSG pattern with q value < 0.05 (Figure 2-2). The most 
frequently non-silently mutated gene was APC, mutated in 16 (45.7%) patients, and all these 16 patients 
carried at least one truncating mutation (nonsense, frameshift, splice site or nonstop mutations). 
KRTAP4-5 was mutated in 6 samples with all mutations being missense and located at a known SNV 
(rs411367). CTNNB1 also exclusively carried missense mutations, and two of these mutations were at   
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Table 2-1. Characteristics of 149 adenoma patients with CNAD and SSA. 
  CNAD (n=135) SSA (n=14) p value* 
Age    
mean 59.3 58.21 0.703  
   
Gender    
Female 58 7  
Male 77 7 0.778 
    
Race    
White 112 13  
Black 15 1  
Other 8 0 <0.001 
 
   
Hispanic or Latino    
Y 10 1  
N 125 13 1 
 
   
Smoking 
   
Never 66 6 
 
Former 50 6  
Current 19 2 <0.001 
 
   
Larger than 10mm 
   
Y 21 3 
 
N 113 11 0.701 
 
  
 
High grade dysplasia 
   
Y 6 0 
 
N 129 14 1 
 
   
Advanced    
Y 30   
N 104     
*: Student’s t test for continuous variables and Fisher’s exact test for categorical variables. CNAD: 
conventional adenoma. SSA: Sessile serrated adenoma. 
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Table 2-2. Characteristics of 378 patients with colorectal cancer. 
  
Hypermutated 
(n=66) 
Non-hypermutated 
(n=312) 
p value 
Age   
 
Mean 65.77 64.92 0.653 
Gender   
 
Female 33 146  
Male 33 166 0.685 
Race   
 
White 36 181  
Black 7 24  
Other 5 6 <0.001 
Hispanic or Latino    
Y 0 2  
N 46 202 1 
Pathology T stage   
 
T1 3 8  
T2 13 60  
T3 43 207  
T4 7 32  
Tis 0 1 <0.001 
Pathology N stage   
 
N0 55 172  
N1 7 85  
N2 4 54  
NX 0 1 <0.001 
Pathology M stage   
 
M0 54 232  
M1 3 44  
MX 6 34 <0.001 
Stage   
 
I 15 58  
II 39 105  
III 8 95  
IV 3 46 <0.001 
*: Student’s t test for continuous variables and Fisher’s exact test for categorical variables 
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Figure 2-1. Frequency of somatic mutations in CRC and adenoma patients.  
 
Number of mutations per million bases: Red, non-silent mutations; Green, silent mutations. 
Microsatellite status (MSI): Red, MSI-H; Orange, MSI-L; Green, MSS; Grey: data not 
available. MLH1 expression (MLH1): Red, up-regulation; Blue, down-regulation; Green: 
normal; Grey, data not available. Pathologic subtypes (Subtype): Yellow, CRC; Blue, SSA; 
Green, CNAD. 
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Figure 2-2. Frequently mutated genes with driver pattern by WES and targeted sequencing in CNAD.  
  
 Driver gene q value: false discovery rate (FDR) of driver gene probability. Genes with q < 1 were included.
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SNV rs121913409 which was reported to be pathogenic in liver cancer (Bläker et al., 1999). Two out of 
three GOLGA8B-mutated CNAD carried a missense SNV (rs200544945). And two out of five missense 
mutations on TMPRSS13 was found at a rare SNV rs61900347. As for SSA, one potential driver gene 
was found with OG pattern: BRAF (Figure 2-3). Seven patients had somatic mutations at the known 
pathogenic locus V600E which was enriched in both SSA and hypermutaters. It is worth noting that 
although KRTAP4-5 was not statistically significant after adjusting for multiple comparison possibly due 
to small sample size, three KRTAP4-5 mutations in SSA were all located at rs411367, just like CNAD, 
suggesting possible enrichment. Due to design of the targeted panel, we were unable to validate the 
mutation prevalence of KRTAP4-5, yet our WES suggested that the possibility of KRTAP4-5 being 
functional in CRC tumorigenesis in both CNAD and SSA warrants further investigation. 
  
2.3.3 Classifiers between CNAD and CRC identifies potential driver genes 
Mutation profiles could clearly classify CNAD and CRC tissues.  We pooled the WES and 
targeted sequencing data for CNAD and compared with the TCGA WES data for CRC. Due to the 
selection of genes of interest in targeted sequencing, popular methods for mutation significance which 
depend on background mutation rate estimation from neighboring genes could not be applied. So we 
chose an implementation of the 20/20 rule (Vogelstein et al., 2013) which was based on mutation 
aggregation (Van den Eynden et al., 2015). Profiles of the mutations identified using TG alone and WES 
combine with TG in CNAD were shown in Figure 2-4 and Figure 2-5. With increased sample size, we 
discovered three genes with driver mutation patterns, KRAS, FBXW7 and SOX9, in addition to those 
implicated in WES. Among the three extra genes, KRAS followed the pattern of OGs with missense 
mutations at the two known pathological SNVs, rs121913529 (Pao et al., 2005) and rs121913530 
(Bourdeaut et al., 2010; Matsuda et al., 2007),. On the other hand, both FBXW7 and SOX9 showed 
mutation patterns of TSGs. With the larger sample size, we were also able to discover that CTNNB1 had 
two recurrent mutations at rs121913412 and rs121913409 which were enriched in CNAD. And these  
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Figure 2-3. Frequently mutated genes with driver pattern by WES and targeted sequencing in SSA by WES. 
 
Driver gene q value: false discovery rate (FDR) of driver gene probability. Genes with q < 1 were listed. 
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Figure 2-4. Frequently mutated genes with driver pattern by WES and targeted sequencing in adenomas by TG. 
 
Driver gene q value: false discovery rate (FDR) of driver gene probability. Genes with q < 0.1 were listed. 
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Figure 2-5. Frequently mutated genes with driver pattern by WES and targeted sequencing in adenomas by WES and TG combined. 
 
Driver gene q value: false discovery rate (FDR) of driver gene probability. Genes with q < 0.1 were listed. 
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And these SNVs have been suggested to be pathogenic in other types of cancer (Bläker et al., 1999; 
Legoix et al., 1999; Shitoh et al., 1999),.  
We used trend test to identify genes with a consistent trend and found five genes, TP53, 
PIK3CA, KRAS, APC and SMAD4, were statistically significant after adjusting for multiple comparison 
(Figure 2-6) (Benjamini and Hochberg, 1995). Differences in the composition of non-silent mutations 
were observed. For instance, TP53 mutations in CNAD were exclusively missense while ¼ of mutations 
in CRC were truncating mutations. A closer look into the missense mutations in CNAD, we found two 
sites, rs28934578 (R175H) and rs28934576 (R273H), that were recurrent in non-hypermutater (26 and 9 
CRC samples, respectively) and were known for modifying the conformation or the DNA-binding 
domain of TP53 (Muller and Vousden, 2014, p. 53).  
To identify the most important genes that significantly differentiate between adenomas and 
CRC, we performed permuted random forest and identified 19 important genes. We then created a model 
to predict malignant progression using these genes.  The AUC of the model reached 0.952 in receiver 
operating characteristics (ROC) procedure with an error rate of 13.66% (model 1, all adenomas vs. 
CRC). If we limit the classification to only non-hypermutated CRC and all adenomas, 22 important 
genes were significant different between the two groups.  The AUC of the refined model reached 0.955 
with an error rate of 14.97% (model 2, all adenomas vs. non-hypermutated CRC). To further lower the 
heterogeneity among adenomas, we also built a classifier with only CNAD and non-hypermutated CRC. 
In this set, 20 genes with non-silent mutations were identified as important variables, the AUC reached to 
0.941 and the error rate based on these genes was 14.54% (model 3, CNAD vs. non-hypermutated CRC, 
Figure 2-7). 16 genes were shared by all three models (Table 2-3), and the 4 genes with the significantly 
consistent trend mentioned above were among these gene panels. 
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Figure 2-6. Frequency and composition of non-silent mutations in genes with a significant trend 
as disease progress.  
 
Left: non-advanced adenoma. Middle: Advanced adenoma. Right: CRC. Diameter of pie charts: 
frequency. Color: mutation type. All genes had trend test q < 0.1. 
  
38 
 
Figure 2-7. Prediction model for malignant progression from CA to non-hypermutated CRC. 
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Table 2-3. Trend test results and important variables in random forest models. 
Gene 
Non-silent 
mutation 
Non-
advanced (# 
of patient) 
Advanced  
(# of 
patient) 
non-
hypermutater 
CRC  
(# of patient) 
Trend test 
p value* 
Trend 
test FDR* 
TP53 N 102 28 120   
 Y 2 2 192 9.80E-29 6.38E-26 
KRAS N 99 22 184   
 Y 5 8 128 5.47E-12 1.78E-09 
APC N 72 8 102   
 Y 32 22 210 4.06E-10 8.80E-08 
PIK3CA N 104 30 239   
 Y 0 0 73 3.74E-09 6.09E-07 
SMAD4 N 104 30 272   
 Y 0 0 40 2.88E-05 3.75E-03 
FBXW7 N 104 26 278   
 Y 0 4 34 1.10E-03 1.09E-01 
CTNNB1 N 91 27 300   
 Y 13 3 12 1.17E-03 1.09E-01 
SYNE1 N 97 27 251   
 Y 7 3 61 1.39E-03 1.13E-01 
CDC27 N 81 23 194   
 Y 23 7 118 2.01E-03 1.45E-01 
CSMD1 N 101 27 270   
 Y 3 3 42 2.68E-03 1.75E-01 
NRAS N 104 30 292   
 Y 0 0 20 3.89E-03 2.30E-01 
RYR3 N 103 29 287   
 Y 1 1 25 7.40E-03 3.21E-01 
NALCN N 104 30 295   
 Y 0 0 17 7.99E-03 3.25E-01 
LRP1B N 98 28 265   
 Y 6 2 47 8.95E-03 3.43E-01 
FAT4 N 99 28 270   
 Y 5 2 42 1.13E-02 3.87E-01 
ATM N 101 30 283   
 Y 3 0 29 1.63E-02 4.46E-01 
TMPRSS13 N 92 27 246   
 Y 12 3 66 1.85E-02 4.81E-01 
SOX9 N 101 29 283   
 Y 3 1 29 2.32E-02 5.22E-01 
CSMD3 N 101 30 286   
 Y 3 0 26 3.14E-02 6.34E-01 
MED12 N 103 30 297   
 Y 1 0 15 4.90E-02 6.66E-01 
*: Chi-square trend test 
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2.4 Discussion 
In this study, we identified potential driver mutations of adenomas via WES and profiled the 
identified driver genes using TS. To the best of our knowledge, the current study has an unparalleled scale 
of both WES and TS of colorectal adenomas. We also reanalyzed publicly available CRC data from TCGA 
using the same pipeline to ensure valid comparisons and the most up-to-date variant discovery. Our study 
had 6 major findings. First, WES revealed similar somatic mutation frequencies in CNAD and SSA. Second, 
all adenomas included in WES were non-hypermutaters, with an average non-silent somatic mutation 
frequency significantly lower than that of CRC non-hypermutaters. Third, CNAD and SSA had both shared 
and unique driver genes, potentially reflecting differences in underlying biology of these lesions. Fourth, 
TS confirmed the WES findings and gave a better estimate of population prevalence of mutations in genes 
of interest. Fifth, a subset of mutations exhibited excellent accuracy for distinguishing between adenoma 
and CRC. Finally, genes displaying a consistent trend in mutation prevalence among non-advanced CNAD, 
advanced CNAD, and CRC could reflect the progress towards malignancy. Collectively, out results 
established the understudied mutation atlas for adenomas.  
We also discovered for the first time that GOLGA8B, TMPRSS13, and KRTAP4-5 have a driver 
pattern in CNAD.  The biological function of both GOLGA8B and TMPRSS13 in the development of 
premalignant lesion in the large intestine is largely unknown. GOLGA8B resides in a region that is 
frequently found to be deleted in newborns with epilepsy and intellectual disability. (Kaminsky et al., 2011) 
TMPRSS13 is also referred to as mosaic serine protease large-form (MSPL), and it has been shown to 
activate pro-hepatocyte growth factor (pro-HGF).(Hashimoto et al., 2010, p. 13) Furthermore, the 
activation of hepatocyte growth factor receptor (encoded by MET proto-oncogene, which is a receptor 
tyrosine kinase for hepatocyte growth factor) by HGF has been shown to rescue colorectal cancer cells from 
the epidermal growth factor receptor inhibitor cetuximab.(Liska et al., 2011) Whether TMPRSS13 promotes 
adenoma development and progression via HGF/MET axis remains to be investigated. KRTAP4-5 belongs 
to the keratin-associated protein family, which contributes to hair structures. A recent publication reported 
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that depletion of the related gene KRTAP5-5 in mammary cancer cells reduced their invasion 
potential.(Berens et al., 2016) 
A widely-accepted model of progression from normal epithelium to adenoma to adenocarcinoma 
was first proposed in 1988. In that model, several genetic alterations, for instance,  5q, 17p, 18q loss and 
RAS mutations, became more prevalent as lesions progressed from class II and class III adenoma to 
adenocarcinoma.(Vogelstein et al., 1988) Subsequent studies refined this model and identified additional 
genetic mutations involved in this process including APC, CTNNB1, CDC4 (FBXW7), PIK3CA, TP53 and 
SMAD4.(Jones et al., 2008) In our study, we also confirmed the presence of truncating mutations in APC 
and activating mutations of CTNNB1 in CNAD. CTNNB1 encodes for β-catenin, and CTNNB1-mutated 
CRCs tend to be highly invasive in patients with Lynch syndrome.(Ahadova et al., 2016, p. 1) Consistent 
with previous findings,(Samowitz et al., 1999) the prevalence of CTNNB1 mutation in the current study 
decreased from 12% in non-advanced CNAD to 7% in advanced CNAD to 3% in CRC. The higher 
prevalence of driver mutations in premalignant lesions than in malignant lesions was also reported and 
discussed by a  recent review.(Kato et al., 2016) One of the examples of this counterintuitive phenomenon, 
referred to as oncogene-induced senescence, was the 70% to 88% prevalence of a mutation of BRAF at 
V600E in melanocytic nevi, a much higher rate than the 40% to 45% found in melanoma samples.(Kato et 
al., 2016) The potential mechanisms underlying oncogene-induced senescence included DNA damage, p38 
activation and formation of heterochromatic foci.(Courtois-Cox et al., 2008) Whether the presence of 
recurrent CTNNB1 mutations in adenoma reflects an early event in polyposis, a bystander mutation, or a 
trigger for oncogene-induced senescence remains to be elucidated. In animal studies, heterozygous 
activating CTNNB1 mutations were unable to deregulate Wnt pathway or confer crypt progenitor cell 
phenotype  unless E-cadherin expression was inhibited suggesting that CTNNB1 mutations alone might not 
be sufficient to drive tumorigenesis.(Huels et al., 2015)  
Previous efforts to identify novel mutations in adenomas using next-generation sequencing(Chen 
et al., 2016; Nikolaev et al., 2012; Vaqué et al., 2015; Zhou et al., 2013) are summarized in Table 2-4. 
Several of the genes in our classifier have previously been found in prior studies on mutations of adenoma  
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Table 2-4. Summary of previous studies exploring mutations in adenoma. 
  Author and Date 
  Nikolaev et al., 2012 Zhou et al., 2013 Vaqué et al., 2015 Chen et al., 2016 
Sequencing and 
sample type 
WES in 1 HP, 16 
CNADs, 1 SSA, 4 
CRCs 
Discovery WES 
in normal tissue, 
CNAD, and CRC 
from 1 patient. 
Validation of 54 
SNVs by TS in 
215 CRCs and 73 
pairs of 
adenomasa and 
CRCs 
WES in 1 HP, 8 
CNADs, and 4 
CRCs from 4 CRC 
patients 
WGS in 2 
CNADs and 2 
SSAs. Whole-
transcriptome 
sequencing in 7 
adenomasb 
Capture probe SureSelect Human 
Exon v3 (Agilent 
Technologies) or 
SeqCap EZ Human 
Exome Library SR 
v1.2 (Roche-
Nimblegen) 
NimbleGen 2.1 
M Human Exome 
Array 
SureSelect Human 
All Exon 
N/A 
Sequencing 
technology 
Illumina HiSeq2000 
and GAIIx. Paired-
end 105 nt . 
Illumina GAII Illumina 
HiSeq2000. 
Paired-end 75 nt 
Not specified 
Depth Polyp depth 155x. 
Normal depth 146x 
CRC depth 
45.12x. CNAD 
99x Not specified 
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depth 46.44x. 
Normal depth 
46.69x 
Bioinformatic 
software 
    
Mapping BWA BWA GEM/BFAST BWA 
SNV calling modified SAMtools 
score 
SAMtools SAMtools In-house 
procedure 
INDEL 
calling 
Pindel N/A N/A not specified 
CNAD Driver 
    
APC CNAD adenoma CNAD CNAD, SSA 
KRTAP4-5 
   
CNAD 
CTNNB1 CNAD 
   
GOLGA8B 
    
TMPRSS13 
    
KRAS CNAD 
 
CNAD 
 
SSA driver 
    
BRAF SSA       
Abbreviations: WES, whole-exome sequencing; CNAD; conventional adenoma; SSA, sessile serrated 
adenoma; CRC, colorectal cancer; SNV, single-nucleotide variant; TS, targeted sequencing; HP, 
hyperplastic polyp ; WGS, whole-genome sequencing; N/A, not applicable  
a The authors did not specify CNAD or SSA, so we use “adenoma.”  
b The comparison was made using whole-genome sequencing rather than whole-exon sequencing results. 
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(APC, CSMD1, CSMD3, CTNNB1, FAT4, FBXW7, KRAS, LRP1B, NRAS, RYR3, SOX9, SYNE1 and TP53). 
We reported several genes that were found to be mutated in CNAD for the first time (ATM, CDC27, MED12, 
NALCN and TMPRSS13). Moreover, the absence of mutations in PIK3CA and SMAD4 in CNAD but 
relatively high frequency in CRC may provide useful translational application as molecular classifier. 
Among the previously unreported genes, TMPRSS13 exhibited a driver-gene pattern in CNADs; most of 
the other genes were predominantly found in CRC. Factors that could contribute to these discrepancies 
include but are not limited to sample size, sequencing technology, and analysis software. In addition to the 
aforementioned reports, a group of our colleagues recently published a study of 25 familial adenomatous 
polyposis (FAP) samples that displayed a mutation rate similar to that in the CNAD samples in the current 
study.(Borras et al., 2016) Both FAP and CNAD had highly prevalent truncating mutations of APC; FBXW7 
mutations were missense in FAP but truncating in CNAD. Transcription factor 7 like 2 (TCF7L2) was 
frequently mutated only in FAP, and no non-silent CCR-4-NOT transcription complex subunit 3 (CNOT3) 
or protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 (PCMTD1) mutations 
occurred in CNAD. These differences in mutated genes may contribute to the distinct disease patterns 
observed in hereditary and sporadic adenomas.In addition to developing a more comprehensive model of 
tumorigenesis which takes into account the heterogeneity of adenoma histology, the current study also 
investigated the mutations in a pathologically distinct subgroup of adenomas with tumorigenic potentials, 
SSAs.(Torlakovic and Snover, 1996) SSA is thought to progress into hypermutated CRC via the serrated 
pathway.(Szylberg et al., 2015) In our study, somatic BRAF mutations at rs113488022 (V600E) were found 
in 50% of SSAs. This somatic mutation was also found in 7of 312 non-hypermutated and 25 of 66 
hypermutater CRCs, suggesting enrichment of mutations at this locus in SSA and hypermutaters. Although 
the prevalence of KRTAP4-5 mutations did not reach significance, possibly because of our small sample 
size, KRTAP4-5 was the only gene found to be frequently mutated in both CNADs and SSAs. Aggregation 
of somatic missense mutations at rs411367, which is found in 1% of the general population, is consistent 
with the pattern found in driver mutations. Future validation of KRTAP4-5 missense mutations is required 
to determine whether this gene serves as a driver in both SSA and CNAD.   
45 
 
In a previous report, analysis of 33 SSA-associated carcinomas, 79% were MLH1-
deficient.(Sweetser et al., 2016) In addition, epigenetic MLH1 downregulation has been implicated in 
hypermutated CRC.(Cancer Genome Atlas Network, 2012) These results seem to support the hypothesis 
that SSA is the precursor for hypermutated CRC. However, our WES demonstrated no significant 
difference in the mutation rates in SSAs and CNADs. In addition, we found no mutations of APC in SSAs. 
This finding appears to contradict the hypothesis that SSA is the origin of hypermutated CRC because APC 
is frequently mutated in hypermutated CRCs.(Cancer Genome Atlas Network, 2012) Whether an SSA 
obtains APC mutation after it progresses to a more advanced lesion or CRC carrying APC mutations 
develops exclusive from CNAD warrants further investigation 
In addition to performing WES, we determined the prevalence of somatic mutations in known 
driver genes in an additional 100 non-advanced and advanced CNAD samples using TS. The combination 
of mutations found in genes covered by both WES and TS provided further insight into when these 
mutations occur. Among genes with a consistent trend, we observed 3 mutation patterns: (1) monotonic 
increasing or decreasing (TP53, CTNNB1 and KRAS); (2) increasing or decreasing from non-advanced to 
advanced CNAD but remaining similar in advanced CNAD and CRC (FBXW7); and (3) remaining similar 
in non-advanced and advanced CNAD but increasing or decreasing from advanced CNAD to CRC 
(PIK3CA and SMAD4). Whether the third group of genes could predict progression from CNAD to CRC 
requires further study. 
To identify the mutational signature of CNAD and compare it with that of CRC, we aggregated the 
WES data on adenocarcinomas from TCGA and our sequencing of adenomas. We expected batch effects 
might lead to false discovery of differently-mutated genes, so we applied several steps to minimize these 
effects, such as using capture probes synthesized by the same supplier (Nimblegen, Roche) and sequencing 
using an Illumina Hiseq 2000 at a similar depth (~100X) and in the same sequencing center following the 
same protocol. We also processed the raw data of TCGA and our own project through the same pipeline. 
When we combined the TS and WES results, we only selected common exon regions for both capture 
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probes. Further validation studies in independent cohorts are needed to evaluate the performance of this 
random forest classifier and establish whether our findings are generalizable. 
We believe that our findings illuminated genetic alterations that mark fundamental differences 
among different types of adenomas and CRC. Our results are based on cross sectional study; we will 
validate the findings in prospective cohort. We will continue to follow the patients in our cohort and 
determine whether adenomas with genetic alterations similar to those found in CRC are associated with 
increased cancer risk. If carrying adenomas with unfavorable genetic alterations does increase cancer risk, 
closer surveillance would be recommended even if the adenomas do not fit the pathologic criteria for 
advanced adenoma. In addition, the novel driver genes we reported in this article could be crucial players 
in the tumorigenesis process, and we plan to collaborate with our colleagues and study the functions of 
these genes in both cell line and animal models to better characterize their roles. 
In conclusion, the data from the current project provide novel insights into potential driver genes 
involved in progression from colorectal adenoma to adenocarcinoma. The genes that differed in the 
mutational profiles of CNAD and CRC could serve as gene panels for early surveillance. Furthermore, 
genes with a clear trend towards malignancy could serve as molecular “clocks” to indicate how far an 
adenoma has progressed towards tumorigenesis. These findings will improve our understanding of the 
underlying biology of CRC, risk stratification, and design of prevention and surveillance programs for CRC. 
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3. Premalignant Transcriptome Atlas of Colorectal Adenoma Reveals 
Difference among Subtypes and Stages 
3.1 Introduction 
 Colorectal adenomas (AD) are the source of colorectal cancer (CRC). Despite the classical model 
of progression proposed back in the 90’ (Fearon and Vogelstein, 1990), efforts to better understand the 
process have continued. With the popularization of colonoscopy which served as both a screening and a 
curative procedure, incidence of CRC have been significantly lowered from 66.3 to 38.3 per 100,000 
(Siegel et al., 2018). However, estimates suggested that even the more advanced AD (ADV) had less than 
6 percent chance of progressing into a malignant tumor (Brenner et al., 2007). Although the low risk did 
not seem to deter people from colonoscopy, the high cost and associated risks have urged scientists to 
come up with a better solution for ages. With deeper understanding of AD pathophysiology, we will have 
a better chance at proposing better surveillance and preventive strategies. 
 There were two major types of AD: conventional (CNAD) and sessile serrated. CNAD can be 
further classified into advanced (ADV) or non-advanced (NAD) depending on criteria such as diameter, 
level of dysplasia and villous constituent. CNAD is found in 20-53% of the US population, and 0.6-7.4% 
of the population had SSA (Abdeljawad et al., 2015; IJspeert et al., 2016; Lash et al., 2010; Strum, 2016) 
which were clearly named since 1996 (Torlakovic and Snover, 1996). Previous studies either focused on 
CNAD or SSA and had relatively small sample size (Delker et al., 2014; Druliner et al., 2018; Kanth et 
al., 2016; Li et al., 2015; Løvf et al., 2014; Mikula et al., 2011; Pesson et al., 2014; Sabates-Bellver et al., 
2007), this creates a barrier for direct comparison of the two subtypes due to possible difference in 
experimental protocol and analytic methodology. In addition, the classification of NAD and ADV were 
purely based on morphology and association with risk of progression. Whether the difference in risk and 
morphology can be explained by molecular pathways remained unanswered. 
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CRC was first classified based on histopathology, but advances in technologies enabled the 
possibility of molecular classification. Researchers speculated that AD follows a similar molecular 
subtype as CRC, yet the validation of this hypothesis is rare (Kanth et al., 2016). Past studies focused on 
identifying AD which gives rise to a certain molecular subtype of CRC, but did not use molecular 
subtypes to differentiate which AD have the potential to progress. The first step in classification was to 
identify and focus on differentially-expressed genes (DEG), yet transcriptome studies of AD were mostly 
looking for DEGs between AD and normal adjacent tissues but not the AD with higher chance of 
progression (Delker et al., 2014; Druliner et al., 2018; Kanth et al., 2016; Li et al., 2015; Løvf et al., 
2014; Mikula et al., 2011; Pesson et al., 2014; Sabates-Bellver et al., 2007). In the premalignant genome 
atlas project in MD Anderson, we aimed at bridging the knowledge gap by high-throughput profiling of 
premalignant lesions using cutting-edge technologies to illuminate the under-studied area of premalignant 
lesions. The current study is the second part of our investigation. We hypothesize that difference between 
AD subtypes offers clues towards comprehensive understanding of AD physiology and will also be 
candidates for biomarkers which can lead to informative design of novel screening and prophylaxis 
measures. To this end, we employed next-generation sequencing to profile transcriptome of NAD, ADV, 
CNAD, and SSA along with paired normal adjacent tissue (NAT) to control for individual difference. The 
obtained data were analyzed following state-of-the-art bioinformatics pipeline developed for the 
International Cancer Genome Consortium (ICGC) in order to obtain the most accurate results which can 
be better compared to data from the largest cancer genomics project, the Cancer Genome Atlas (TCGA). 
 
3.2 Material and Methods 
3.2.1 Study population 
The Premalignant Genome Atlas at the MD Anderson Cancer Center enrolled patients with 
multiple types of premalignant lesions. For the colorectal adenoma subproject, patients who visit MD 
Anderson for colonoscopy were invited to participate. If the patient consent to enrollment, part of the 
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removed polyps along with a small piece of normal intestine mucosa (referred to as NAT) were frozen in 
liquid nitrogen until further use. And a professional interviewer would obtain demographic information 
and disease history from the participant. The selection of samples for transcriptome profiling excluded 
patients with Lynch Syndrome, patients who had prior colorectal cancer, patient who were known to 
receive chemotherapy and patients with liquid tumors. There were no limitation on age, ethnicity, race or 
gender. The selected samples were from patients who underwent colonoscopy and had polyps removed 
from 2010 to 2014. Advanced adenomas in conventional adenomas were defined as adenomas with larger 
than 1cm diameter, high grade dysplasia or classified as villous adenoma (Brenner et al., 2007). 
3.2.2 Whole transcriptome sequencing 
 RNA was extracted by AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, MD, USA) according 
to manufacturer’s instructions. In brief, tissues were removed from liquid nitrogen, disrupted and 
homogenized in buffer RLT provided in the kit. Pass lysate through AllPrep DNA Mini spin column 
using centrifuge at 20000g for 30 seconds. Add proteinase K and ethanol to the flow-through and 
incubate at temperature for 10 minutes. Add extra ethanol and transfer the mixture to RNeasy Mini spin 
column. Spin the column for 15 seconds at 20000g and discard the flow-through. Wash the column once 
with buffer RPE, add DNase I diluted in buffer RDD and DNase I incubation mix. Incubate at room 
temperature for 15 minutes. Add buffer FRN and centrifuge for 15 seconds at 20000g. Pass the flow-
through through the column again and discard the flow-through. Wash the column with buffer RPE, and 
ethanol. Finally, elute the RNA by passing RNase-free water through the column at 8000g for 1 minute. 
Quality of RNA was determined by TapeStation 2100 (Agilent, CA, USA). The quality metrics included 
concentration, 28S/18S, 23S/16S and RNA number (RIN) (Imbeaud et al., 2005). RNA samples were 
submitted to BGI for transcriptome sequencing. After receiving the samples, quality was re-confirmed 
using TapeStation, and then samples were size selected using PAGE gel. All fragments larger than 30bp 
were recovered and subjected to library preparation using TruSeq Stranded mRNA library preparation kit 
(Illumina, CA, USA) following the reference manual. In short, DNase I was added to samples to digest 
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DNA, and magnetic beads coated with poly (T) probes were mixed with sample solution to capture 
mRNA with poly (A) tails. The captured mRNA was eluted and fragmented using Covaris sonicator 
(Covaris, MA, USA). After that, mRNA fragments were subjected to reverse transcription using random 
hexamer as primers followed by a second PCR amplification. End repair and 3’ adenylation were 
performed on PCR product, and adpators were ligated. Ran the ligated library on agarose gel and 
performed further amplification if necessary. After library preparation, quality of library was measured 
using TapeStation. Libraries that passed QC (concentration > 30nM and fragment size was between 100 
and 500 bp) were sequenced. 100-bp paired-end sequencing was performed on Illumina Hiseq 4000 with 
8 samples per lane. Quality measure of the sequencing output included Q20 percentage > 85%, GC 
content between 40 and 55%, and overall number of reads exceed 30 million. Sequencing that did not 
meet this standard were repeated. After demultiplex and removal of barcodes, the reads were stored in 
fastq format. Transcriptome data on TCGA colorectal cancer patients was downloaded from genome data 
commons, and we chose 50 samples with data on paired CRC and NAT (GDC, dbGaP Study Accession: 
phs000178.v9.p8). 
3.2.3 Identification of Differentially Expressed Genes and Pathway Enrichment Analysis 
 Fastq reads were mapped and gene expression was quantified according to the International 
Cancer Genome Consortium (ICGC) pipeline. We validated this pipeline on selected TCGA CRC raw 
data and verified that we could reproduce the same quantification as the GDC before applying the 
pipeline to our dataset. Therefore, all quantified results from CRC were used for further analysis. For raw 
transcriptome sequencing data on AD samples, the fastq reads were searched against a predefined suffix 
array build upon human genome GRCh38.d1.vd1 using STAR aligner (Dobin et al., 2013). The 
GRCh38.d1.vd1 was comprised of human genome GRCh38 without alternate contigs, sequence decoys 
and virus sequences. STAR employed a 2-phase design of mapping where the first phase searches for 
maximal mappable prefix for all reads, and the second phase stitches alignments together and score each 
alignment to find the best match. The aligned reads were stored in BAM format and sorted by read name 
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using samtools (Li et al., 2009). After that, mapped reads were quantified against gencode v22 annotation 
(Harrow et al., 2012) using HTSeq count (Anders et al., 2015).  
 Difference of patient characteristics was compared between CNAD and SSA using student’s t test 
for continuous variables and Fisher’s exact test for categorical variables. The raw read counts were 
analyzed by DESeq2 (Love et al., 2014) to identify differentially expressed genes (DEG). All raw counts 
were first normalized by the overall library size of each sample and log transformed. Then a generalized 
linear model (GLM) was applied on each gene to with the transformed gene counts as dependent variable 
and experiment design factors as independent variables. Gene counts were assumed to follow a negative 
binomial distribution, and coefficients of each design factor reflects the impact on log2 fold change of 
transformed gene counts. False discovery rate was calculated based on Benjamini and Hochberg’s method 
to determine significance (Benjamini and Hochberg, 1995). 
 Permuted random forest models (Archer, 2016) was applied on counts after regularized log (rlog) 
transformation which rendered the counts homoscedastic as suggested in the DESeq2 publication (Love et 
al., 2014, p. 2). Hierarchical clustering was performed on the Euclidean distance between transformed 
counts with FDR < 0.1 and log fold change > 2. And a statistical test to identify overrepresented Gene 
Ontology (GO) Molecular Function (The Gene Ontology Consortium, 2017) was performed on these 
genes in PANTHER 13.1 (Mi et al., 2017). In order to prevent redundancy, we only presented the most 
specific molecular functions when a broader function was significant as well. And molecular functions 
with more than 500 genes were excluded due to the non-informative nature of overly broad functional 
annotation. 
 
3.3 Results 
3.3.1 Patient Characteristics and sequencing metrics 
Patient characteristics of AD patients from our study and CRC patients from TCGA were detailed 
in Table 3-1 and Table 3-2. Our study contained 63 patients with CNAD, 9 with SSA and 50 CRC 
52 
 
patients from TCGA. The mean age for patients with CNAD and SSA were 58.88 and 54.44, respectively. 
The majority of our cohort was Caucasian (87.3% in CNAD and 100% in SSA), and 24 out of 63 CNAD 
were advanced adenoma. No significant differences were observed between CNAD and SSA except for 
smoking status possibly due to the small sample size. As for paired cases of CRC, there was no evidence 
for difference among gender, race or ethnicity as compared to CNAD and SSA. The majority of CRC 
samples were stage T3 (n = 35, 70%), N0 (n = 34, 68%) and M0 (n = 35, 71.4%). The transcriptome 
sequencing yielded between 59-116 million reads with a median of 77 million reads per sample. Among 
these reads, the median percentage of mapped reads was 99.28% ranging from 82.27% to 99.72%. 
Properly paired percentage ranged from 86 to 99.51% with a median of 98.69%. There were no 
significant difference in total reads, percent mapped reads or percent properly paired reads between 
normal and adenoma, CNAD and SSA, ADV and NAD.   
3.3.2 Transcriptome sequencing revealed distinct DEGs for different pathology 
After processing the raw counts, we were able to identify DEGs between premalignant lesion and 
adjacent normal tissue in non-advanced adenoma (NAD), advanced adenoma (ADV), CNAD and SSA. 
Setting the log2 fold change threshold at 2 and FDR at 0.05 yielded 1574 DEGs in ADV and 739 in NAD 
(Figure 3-1). GO molecular functions enriched with these DEGs were listed in Table 3-3 and Table 3-4. 
Among the DEGs in NAD and ADV, 635 were shared by both (37.8%), and they were all in the same 
direction of fold change. The shared DEGs were overrepresented in hormone, growth actor, heparin binding, 
ion channel, and chemokine activities (Table 3-5). 104 (6.2%) DEGs were found exclusively in NAD while 
939 (56%) were only found in ADV. From the list of pathways enriched with ADV-specific genes, antigen 
binding and immunoglobulin binding was overrepresented suggesting a more significant alteration to 
immune-related genes in ADV (Table 3-6). Besides, signaling of serine-type endopeptidase and 
sulfotransferase activities was also modified only in ADV. 
As for CNAD and SSA, the prior had 897 and the latter had 648 DEGs (Figure 3-2). Enriched 
molecular functions were shown in Table 3-7 and Table 3-8. Both the number of overlap (315, 25.6%) of  
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Figure 3-1. Venn diagram of DEGs in ADV and NAD 
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Figure 3-2. Venn diagram of DEGs in CNAD and SSA 
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Table 3-1. Patient characteristics for CNAD and SSA.  
  CNAD (n=63) SSA (n=9) p* 
Age at diagnosis   
 
mean 58.88 54.44 0.108     
Gender 
   
Female 28 (44.4) 3 (33.3) 
 
Male 35 (55.6) 6 (66.7) 0.723  
  
 
Race 
   
White 50 (87.3) 9 (100.0) 
 
Black 5 (7.9) 0 (0) 
 
Hispanic 5 (7.9) 0 (0) 1  
  
 
Advanced 
 
Y 24 (38.1) NA 
 
N 39 (61.9) NA 
 
    
Prior cancer   
 
Y 25 (39.7) 5 (55.6) 
 
N 38 (60.3) 4 (44.4) 0.476 
    
Smoking   
 
Current 6 (9.7) 2 (25.0) 
 
Former 21 (33.9) 5 (62.5) 
 
Never 35 (56.5) 1 (12.5) 0.037 
*: Fisher exact test for categorical variables and student’s t test for continuous variables. 
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Table 3-2. Patient characteristics for CRC. 
 CRC (n=50) 
Age at diagnosis  
mean 69.62  
 
Gender  
Female 27 
Male 23 
  
Race  
White 22 
Black 3 
Other 1 
 
 
Ethnicity  
Hispanic or Latino 0 
Not Hispanic nor Latino 25 
 
 
Pathology T stage  
T1 2 
T2 7 
T3 35 
T4 5 
T4b 1 
 
 
Pathology N stage  
N0 34 
N1 7 
N1a 1 
N2 6 
N2b 2 
 
 
Pathology M stage  
M0 35 
M1 8 
MX 6 
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Table 3-3. GO Molecular functions enriched with DEGs of ADV 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0003823 antigen binding  90 12.71 + 7.08 7.10E-41 3.27E-37 
GO:0004252 serine-type endopeptidase activity  66 14.97 + 4.41 9.93E-21 1.52E-17 
GO:0034987 immunoglobulin receptor binding  24 3.77 + 6.36 4.56E-11 1.62E-08 
GO:0008201 heparin binding  35 9.23 + 3.79 4.28E-10 1.23E-07 
GO:0004984 olfactory receptor activity  3 24.89 - 0.12 1.53E-07 2.20E-05 
GO:0140098 catalytic activity, acting on RNA  4 22.11 - 0.18 7.48E-06 7.49E-04 
GO:0008009 chemokine activity  13 2.84 + 4.57 2.56E-05 2.36E-03 
GO:0008083 growth factor activity  25 9.52 + 2.63 6.34E-05 5.12E-03 
GO:0022843 voltage-gated cation channel 
activity  
22 8.24 + 2.67 9.41E-05 7.22E-03 
GO:0005179 hormone activity  20 7.2 + 2.78 1.19E-04 8.29E-03 
GO:0005231 excitatory extracellular ligand-
gated ion channel activity  
12 2.9 + 4.14 1.18E-04 8.38E-03 
GO:0022824 transmitter-gated ion channel 
activity  
12 2.9 + 4.14 1.18E-04 8.51E-03 
GO:0045236 CXCR chemokine receptor 
binding  
7 0.93 + 7.54 1.65E-04 1.10E-02 
GO:0008146 sulfotransferase activity  12 3.02 + 3.98 1.63E-04 1.10E-02 
GO:0042165 neurotransmitter binding  12 3.02 + 3.98 1.63E-04 1.12E-02 
GO:0015081 sodium ion transmembrane 
transporter activity  
23 9.11 + 2.52 1.77E-04 1.16E-02 
GO:0140097 catalytic activity, acting on DNA  1 11.66 - 0.09 2.60E-04 1.66E-02 
GO:0005201 extracellular matrix structural 
constituent  
14 4.53 + 3.09 4.72E-04 2.82E-02 
GO:0070405 ammonium ion binding  13 4.18 + 3.11 7.07E-04 3.88E-02 
GO:0005254 chloride channel activity  14 4.76 + 2.94 7.31E-04 3.96E-02 
GO:0032549 ribonucleoside binding  8 22.63 - 0.35 7.98E-04 4.17E-02 
GO:0004842 ubiquitin-protein transferase 
activity  
10 25.76 - 0.39 7.94E-04 4.20E-02 
GO:0004518 nuclease activity  2 12.65 - 0.16 8.31E-04 4.30E-02 
GO:1901618 organic hydroxy compound 
transmembrane transporter activity  
10 2.73 + 3.67 9.70E-04 4.96E-02 
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Table 3-4. GO Molecular functions enriched with DEGs of NAD 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0008381 mechanosensitive ion channel 
activity  
28 9 + 3.11 3.96E-07 1.40E-04 
GO:0022839 ion gated channel activity  27 8.92 + 3.03 1.04E-06 3.19E-04 
GO:0005254 chloride channel activity  13 2.22 + 5.86 1.24E-06 3.55E-04 
GO:0008201 heparin binding  17 4.3 + 3.95 4.36E-06 1.12E-03 
GO:0005179 hormone activity  14 3.35 + 4.18 1.73E-05 2.95E-03 
GO:0140098 catalytic activity, acting on 
RNA  
0 10.3 - < 0.01 6.51E-05 8.56E-03 
GO:0008083 growth factor activity  15 4.43 + 3.38 8.29E-05 1.06E-02 
GO:0046873 metal ion transmembrane 
transporter activity  
28 12.25 + 2.29 1.18E-04 1.39E-02 
GO:0008009 chemokine activity  8 1.33 + 6.04 1.17E-04 1.45E-02 
GO:0004984 olfactory receptor activity  1 11.6 - 0.09 2.01E-04 2.31E-02 
GO:0005261 cation channel activity  21 8.55 + 2.46 3.74E-04 4.10E-02 
GO:0008188 neuropeptide receptor activity  7 1.24 + 5.63 4.56E-04 4.88E-02 
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Table 3-5. GO Molecular functions enriched with DEGs shared by both ADV and NAD 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0005179 hormone activity  14 3.01 + 4.66 5.21E-06 1.26E-03 
GO:0008201 heparin binding  16 3.85 + 4.15 4.40E-06 1.27E-03 
GO:0008381 mechanosensitive ion channel 
activity  24 8.07 + 2.97 5.05E-06 1.29E-03 
GO:0022839 ion gated channel activity  23 8 + 2.88 1.32E-05 3.03E-03 
GO:0005254 chloride channel activity  10 1.99 + 5.03 6.40E-05 1.02E-02 
GO:0046873 metal ion transmembrane 
transporter activity  26 10.98 + 2.37 9.30E-05 1.34E-02 
GO:0008083 growth factor activity  14 3.97 + 3.52 9.12E-05 1.35E-02 
GO:0140098 catalytic activity, acting on 
RNA  0 9.23 -  < 0.01 2.22E-04 2.76E-02 
GO:0008009 chemokine activity  7 1.19 + 5.89 3.39E-04 4.00E-02 
GO:0005261 cation channel activity  19 7.66 + 2.48 4.32E-04 4.97E-02 
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Table 3-6. GO Molecular functions enriched with DEGs only found in ADV 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0003823 antigen binding  89 7.44 + 11.96 8.56E-59 3.94E-55 
GO:0004252 serine-type endopeptidase activity  54 8.77 + 6.16 6.71E-24 1.54E-20 
GO:0034987 immunoglobulin receptor binding  24 2.21 + 10.87 7.43E-16 5.70E-13 
GO:0008201 heparin binding  19 5.4 + 3.52 6.79E-06 1.74E-03 
GO:0004984 olfactory receptor activity  2 14.58 - 0.14 1.04E-04 1.71E-02 
GO:0008146 sulfotransferase activity  9 1.77 + 5.09 1.60E-04 2.45E-02 
GO:0140135 
mechanosensitive cation channel 
activity  20 7.82 + 2.56 2.42E-04 2.93E-02 
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Table 3-7. GO Molecular functions enriched with DEGs of CNAD 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0008201 heparin binding  20 5.27 + 3.79 1.35E-06 3.27E-04 
GO:0005179 hormone activity  16 4.11 + 3.89 1.14E-05 1.81E-03 
GO:0005254 chloride channel activity  13 2.72 + 4.78 1.07E-05 1.82E-03 
GO:0140135 mechanosensitive cation channel 
activity  21 7.63 + 2.75 6.56E-05 7.55E-03 
GO:0048306 calcium-dependent protein binding  10 1.99 + 5.02 7.61E-05 8.54E-03 
GO:0005231 excitatory extracellular ligand-
gated ion channel activity  9 1.66 + 5.43 1.03E-04 1.03E-02 
GO:0140098 catalytic activity, acting on RNA  1 12.64 - 0.08 9.58E-05 1.03E-02 
GO:0022824 transmitter-gated ion channel 
activity  9 1.66 + 5.43 1.03E-04 1.05E-02 
GO:0042165 neurotransmitter binding  9 1.72 + 5.22 1.34E-04 1.31E-02 
GO:0015081 sodium ion transmembrane 
transporter activity  16 5.21 + 3.07 1.51E-04 1.45E-02 
GO:0008083 growth factor activity  16 5.44 + 2.94 2.38E-04 2.07E-02 
GO:0004089 carbonate dehydratase activity  
5 0.46 + 
10.7
7 2.69E-04 2.29E-02 
GO:0070405 ammonium ion binding  10 2.39 + 4.19 2.91E-04 2.35E-02 
GO:0000978 RNA polymerase II proximal 
promoter sequence-specific DNA 
binding  28 13.2 + 2.12 3.95E-04 3.14E-02 
GO:0000982 transcription factor activity, RNA 
polymerase II proximal promoter 
sequence-specific DNA binding  28 13.27 + 2.11 4.13E-04 3.22E-02 
GO:0008009 chemokine activity  8 1.63 + 4.92 4.47E-04 3.26E-02 
GO:0017171 serine hydrolase activity  22 9.65 + 2.28 5.66E-04 4.01E-02 
GO:0005244 voltage-gated ion channel activity  17 6.57 + 2.59 6.06E-04 4.16E-02 
GO:0005525 GTP binding  2 12.7 - 0.16 6.29E-04 4.26E-02 
GO:0001102 RNA polymerase II activating 
transcription factor binding  7 1.33 + 5.28 7.02E-04 4.49E-02 
GO:0004984 olfactory receptor activity  3 14.23 - 0.21 7.92E-04 4.93E-02 
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Table 3-8. GO Molecular functions enriched with DEGs of SSA 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0008201 heparin binding  17 4.24 + 4.01 3.63E-06 9.29E-04 
GO:0005249 voltage-gated potassium channel 
activity  12 2.51 + 4.79 2.00E-05 2.97E-03 
GO:0008392 arachidonic acid epoxygenase 
activity  6 0.48 + 12.5 2.70E-05 3.88E-03 
GO:0001664 G-protein coupled receptor binding  19 7.15 + 2.66 1.98E-04 2.46E-02 
GO:0001077 transcriptional activator activity, 
RNA polymerase II proximal 
promoter sequence-specific DNA 
binding  19 7.33 + 2.59 2.69E-04 3.25E-02 
GO:0008188 neuropeptide receptor activity  7 1.23 + 5.71 4.20E-04 4.60E-02 
GO:0046943 carboxylic acid transmembrane 
transporter activity  13 4.08 + 3.19 4.11E-04 4.73E-02 
GO:0004222 metalloendopeptidase activity  11 3.09 + 3.56 4.83E-04 4.94E-02 
GO:0005125 cytokine activity  16 5.87 + 2.73 4.76E-04 4.98E-02 
GO:0015291 secondary active transmembrane 
transporter activity  17 6.45 + 2.63 4.65E-04 4.98E-02 
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DEGs and the molecular function associated with subtype-specific DEGs suggested that the two subtypes 
differs from each other in gene expression (Table 3-9 and Table 3-10). The shared DEGs by both subtypes 
were almost all in the same direction of fold change (312 out of 315, 99.0%), but were not overrepresented 
with particular molecular functions except for heparin binding (FDR < 5x10-3). In general, DEGs in SSA 
were uniquely associated with arachidonic acid epoxygenase and metal ion transmembrane transporter. On 
the other hand, CNAD seemed associated with chloride channel, neurotransmitter and hormone. 
With the same threshold on fold change and FDR, the number of DEGs in CRC was 4372, showing 
a much more disturbed gene expression profile. Figure 3-3 shows the DEGs that were shared and exclusive 
for CRC and CNAD. CRC contributed 80.1% to the union of DEGs in both groups, and the overlapping 
DEGs were twice more than that of CNAD exclusive DEGs. The molecular functions enriched with CRC 
exclusive DEGs were listed in Table 3-11. These molecular functions might reflect the missing pieces for 
CNAD to obtain in its way to malignancy. The same observation holds true for SSA as demonstrated in 
the Venn diagram (Figure 3-4) and the GO molecular function enrichment list (Table 3-12). If we compare 
Table 3-11 and Table 3-12, we could see that the majority of molecular functions yet to be altered for 
CNAD and SSA had a lot in common. These missing pieces include dysregulation of genes related to 
antigen, calcium ion, calmodulin, nucleotide, chromatin and TGF-β receptor binding as well as G-protein 
coupled receptor, ribosome, ion channel, growth factor, and glutamate receptor activities. However, SSA 
seemed to be missing a couple additional dysregulated molecular functions like acetylcholine receptor, 
protein kinase and small GTPase signaling. The quantity of DEGs shared with NAD and ADV were 
illustrated in Figure 3-5. Compared to ADV and CRC, NAD had considerably less exclusive DEGs, and 
the majority of NAD DEGs were shared with ADV and CRC possibly reflecting the fact that NAD was 
the earliest stage in tumorigenesis. Nevertheless, the Venn diagram of CRC, SSA and CNAD showed SSA 
is a separate entity with slightly more exclusive DEGs as CNAD (Figure 3-6).  
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Figure 3-3. Venn diagram of DEGs in CRC and CNAD 
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Figure 3-4. Venn diagram of DEGs in CRC and SSA 
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Figure 3-5. Venn diagram of DEGs in CRC, ADV and NAD 
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Figure 3-6. Venn diagram of DEGs in CRC, CNAD and SSA 
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Table 3-9. GO Molecular functions enriched with DEGs only found in CNAD 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0005254 chloride channel activity  11 1.65 + 6.66 2.24E-06 6.86E-04 
GO:0005231 
excitatory extracellular ligand-gated 
ion channel activity  7 1.01 + 6.95 1.26E-04 2.15E-02 
GO:0022824 
transmitter-gated ion channel 
activity  7 1.01 + 6.95 1.26E-04 2.23E-02 
GO:0042165 neurotransmitter binding  7 1.05 + 6.68 1.57E-04 2.58E-02 
GO:0008083 growth factor activity  12 3.3 + 3.63 2.06E-04 3.16E-02 
GO:0005179 hormone activity  10 2.5 + 4 3.36E-04 4.69E-02 
GO:0005261 cation channel activity  17 6.37 + 2.67 3.68E-04 4.98E-02 
 
  
69 
 
Table 3-10. GO Molecular functions enriched with DEGs only found in SSA 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0008392 arachidonic acid epoxygenase 
activity  
6 0.25 + 24.44 6.18E-07 2.85E-03 
GO:0046873 metal ion transmembrane 
transporter activity  
19 6.18 + 3.08 2.40E-05 1.38E-02 
GO:0022832 voltage-gated channel activity  12 2.7 + 4.44 2.94E-05 1.50E-02 
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Table 3-11. GO Molecular functions enriched with DEGs in CRC but not CNAD 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0003823 antigen binding  36 9.49 + 3.79 7.33E-10 7.04E-08 
GO:0015276 ligand-gated ion channel activity  30 12.32 + 2.43 4.97E-05 1.59E-03 
GO:0008066 glutamate receptor activity  14 3.56 + 3.93 8.32E-05 1.77E-03 
GO:0004930 G-protein coupled receptor activity  53 28.21 + 1.88 7.24E-05 1.99E-03 
GO:0005509 calcium ion binding  38 18.81 + 2.02 1.73E-04 2.76E-03 
GO:0005249 voltage-gated potassium channel 
activity  
17 5.75 + 2.96 2.80E-04 4.14E-03 
GO:0003723 RNA binding  15 35.15 - 0.43 3.42E-04 4.38E-03 
GO:0016301 kinase activity  31 57.06 - 0.54 3.28E-04 4.50E-03 
GO:0005516 calmodulin binding  25 10.77 + 2.32 3.77E-04 4.52E-03 
GO:0003735 structural constituent of ribosome  2 11.5 - 0.17 2.01E-03 2.27E-02 
GO:0003682 chromatin binding  5 16.16 - 0.31 2.91E-03 2.94E-02 
GO:0016247 channel regulator activity  7 1.73 + 4.04 4.51E-03 4.12E-02 
GO:0000989 transcription factor binding 
transcription factor activity  
9 21.55 - 0.42 5.07E-03 4.43E-02 
GO:0008083 growth factor activity  12 4.66 + 2.58 5.48E-03 4.57E-02 
GO:0005160 transforming growth factor beta 
receptor binding  
9 2.92 + 3.08 5.92E-03 4.73E-02 
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Table 3-12. GO Molecular functions enriched with DEGs in CRC but not SSA 
GO id Molecular Function obs exp +/- FC raw P* FDR 
GO:0003823 antigen binding  36 10.41 + 3.46 7.00E-09 4.48E-07 
GO:0015276 ligand-gated ion channel activity  35 13.52 + 2.59 5.07E-06 1.39E-04 
GO:0005509 calcium ion binding  46 20.63 + 2.23 4.51E-06 1.44E-04 
GO:0004930 G-protein coupled receptor activity  61 30.94 + 1.97 6.08E-06 1.46E-04 
GO:0008066 glutamate receptor activity  16 3.91 + 4.1 2.00E-05 3.84E-04 
GO:0003723 RNA binding  15 38.55 - 0.39 4.73E-05 7.57E-04 
GO:0005516 calmodulin binding  28 11.82 + 2.37 1.32E-04 1.82E-03 
GO:0008083 growth factor activity  15 5.11 + 2.94 7.14E-04 8.07E-03 
GO:0003735 structural constituent of ribosome  2 12.62 - 0.16 9.59E-04 9.21E-03 
GO:0003682 chromatin binding  5 17.72 - 0.28 1.08E-03 9.88E-03 
GO:0015464 acetylcholine receptor activity  6 1 + 5.99 2.03E-03 1.69E-02 
GO:0005249 voltage-gated potassium channel 
activity  
16 6.31 + 2.54 2.31E-03 1.85E-02 
GO:0004672 protein kinase activity  23 41.46 - 0.55 3.24E-03 2.49E-02 
GO:0005083 small GTPase regulator activity  5 16.02 - 0.31 3.90E-03 2.68E-02 
GO:0003712 transcription cofactor activity  8 20.53 - 0.39 3.85E-03 2.74E-02 
GO:0005160 transforming growth factor beta 
receptor binding  
10 3.2 + 3.12 3.73E-03 2.75E-02 
GO:0045182 translation regulator activity  1 8.01 - 0.12 6.31E-03 3.91E-02 
GO:0016247 channel regulator activity  7 1.9 + 3.68 7.16E-03 4.29E-02 
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Finally, we previously reported somatically mutated genes which could separate CNAD from CRC 
(Lin et al., 2017). We assume that if these genes were truly biologically relevant, they might be capable of 
differentiating CNAD and CRC in RNA expression level. A preliminary look at the expression of these 
genes in CNAD and CRC seemed to suggest that these genes had opposite expression ratios when 
normalized by expression in the NAT from the same patient (Table 3-13). Random forest model was fitted 
on the expression ratio, and a 96.85% accuracy and > 99% AUC (Figure 3-7) were obtained suggesting 
that expression of the somatic mutation classifier genes is altered as well. 
 
3.4 Discussion 
Our investigation on the transcriptome of malignant/premalignant and NAT found gene sets 
which represented the specific pathophysiology of different subtypes of colorectal adenomas and CRC. 
NAD and ADV shared multiple molecular functions as shown in Table 3-5. Among the top molecular 
functions, heparin binding-related genes were overrepresented in DEGs. Heparin has been prescribed 
after surgical removal of tumors to prevent thromboemboli (Wille-Jørgensen et al., 2003) with 
controversial evidence on effectiveness (Sanford et al., 2014). However, a couple in vitro studies found 
that heparin promotes the growth of human colorectal cancer cell lines, HT29, SW1116, and HCT116 
(Chatzinikolaou et al., 2008) possibly via p38 MAPK pathway (Chatzinikolaou et al., 2010). Another 
literature found that the activity of heparin on colorectal cancer cell lines might be altered by the 6-O-
sulfates functional group and the expression of Sulfatases (Vicente et al., 2015). Mechanosensitive ion 
channel, ion-gated channel, metal ion transporter and cation channel are a series of molecular functions 
enriched within DEGs shared by NAD and ADV. Chloride channel accessory 1 (CLCA1) is mainly 
expressed in colon, and has been shown to be linked to differentiation of colorectal cancer cells (Yang et 
al., 2013). In addition, CRC patients with lower expression of CLCA1 had worse prognosis (Yang et al., 
2015). Besides chloride channels, one recent study reported that mechanical force has been shown to 
stimulate colorectal cancer cell line growth possibly via calcium ion influx through ion channel Cav3.3 
and subsequent activation of PKCβ and NF-κB (Basson et al., 2015). Another pressure-activated channel 
Piezo1 were found mutated frequently in familiar adenomatous polyposis (Spier et al., 2016). Further  
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Figure 3-7. ROC curve and confusion matrix for random forest model classifying CNAD and 
CRC 
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Table 3-13. Gene expression of previously reported classifier genes in CRC and CNAD 
 
CNAD/NAT  CRC/NAT 
Gene FC FDR  FC FDR 
APC 1.43 ▲ 2.75x10-7 
 
0.46 ▼ 1.17x10-18 
ATM 0.83 ▼ 3.22x10-2 
 
0.88 
 
0.175 
CDC27 0.89 ▼ 4.22x10-3 
 
1.06 
 
0.507 
CSMD1 1.43 ▲ 0.132 
 
0.26 ▼ 1.33x10-11 
CSMD3 1.67 ▲ 7.57x10-5 
 
0.78 
 
0.410 
CTNNB1 1.02 
 
0.6 
 
1.61 ▲ 2.96x10-15 
FAT4 1.34 ▲ 5.39x10-3 
 
0.45 ▼ 4.95x10-7 
FBXW7 1.08 
 
0.145 
 
0.90 
 
0.061 
KRAS 1.54 ▲ 2.40x10-18 
 
0.60 ▼ 5.27x10-15 
LRP1B 1.83 ▲ 0.048 
 
0.13 ▼ 1.61x10-14 
MED12 0.98 
 
0.703 
 
1.38 ▲ 3.36x10-4 
NALCN 1.19 
 
0.226 
 
1.04 
 
0.883 
NRAS 1.09 
 
0.051 
 
0.78 ▼ 2.04x10-3 
PIK3CA 1.02 
 
0.818 
 
0.79 ▼ 2.38x10-3 
RYR3 1.06 
 
0.816 
 
0.16 ▼ 4.82x10-30 
SMAD4 0.94 
 
0.227 
 
0.66 ▼ 2.97x10-10 
SOX9 0.44 ▼ 3.12x10-20 
 
4.24 ▲ 6.39x10-48 
SYNE1 1.52 ▲ 1.05x10-5 
 
0.35 ▼ 3.91x10-17 
TMPRSS13 0.20 ▼ 1.16x10-26 
 
11.9
4 
▲ 1.05x10-38 
TP53 0.59 ▼ 6.06x10-25 
 
1.58 ▲ 3.36x10-5 
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mechanistic and animal studies are required to explore the possible roles heparin might play in the 
adenoma-cancer sequence. Chemokine activity-related genes were among the enriched molecular 
functions as well. A study published in 2014 demonstrated that one of the most popular mouse model for 
colorectal cancer carrying APC point mutation, Apc(Min/+), seemed to have altered chemokine 
expression profile and recruitment of possibly T regulatory cells (Akeus et al., 2014). Another group 
reported that CXCL1 and CXCL5 expression was associated with CRC and its liver metastasis (Rubie et 
al., 2008). In Table 3-6, DEGs present in ADV but not NAD were analyzed for overrepresented 
molecular functions. Immune-related functions like antigen and immunoglobulin binding were at the top 
of the list. Additionally, previously mentioned heparin- and sulfotransferase-related molecules were 
overrepresented in ADV showing the evolution towards malignancy. Besides, serine-type endopeptidase 
appeared at advanced stage of adenomas, and the association between protease and colorectal cancers 
have been summarized previously (Herszényi et al., 2014). In sum, proteases have several aspects of 
function which favor tumorigenesis: dissolves extra cellular matrix (ECM), activates adhesion molecules 
and growth factors, inhibition of apoptosis, disruption of chemokine and alters angiogenesis.  
 Another set of analysis performed in our study focused on the difference between SSA and 
CNAD. As a relatively new category of colorectal adenoma, studies on SSA is much less than that on 
CNAD. The molecular mechanism for SSA has been suggested to start with BRAF mutation which 
triggers downstream signaling of MAPK cascade leading to decreased apoptosis (Dekker and IJspeert, 
2017). The relative small sample size of our previous work (Lin et al., 2017) identified BRAF mutation 
the most frequent in SSA, and now we further investigate the DEGs in SSA to provide a more 
comprehensive characterization of molecular alterations. Besides ion channel-related molecular 
functions, a unique pathway stood out: arachidonic acid epoxygenase activity (Table 3-10). Arachidonic 
acid is a main constituent of fat in eggs and meats, and it can be metabolized by arachidonic acid 
epoxygenase to produce epoxyeicosatrienoic acids (EETs). EETs can promote growth and mobility of 
cancer cell lines (Jiang et al., 2007, 2005, p. 450), and an animal studies demonstrated that 
intraperitoneal injection of EETs might lead to metastasis (Panigrahy et al., 2012). To the best of our 
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knowledge, EETs have not been linked to SSA. It would be interesting to investigate the potential impact 
from arachidonic acid metabolism in the formation of SSA or the progression towards CRC from SSA. 
 Finally, the comparison between adenoma subtypes and CRC provided the insight into molecular 
functions which premalignant lesions have not been able to harness or have not disturbed such functions 
enough to their own advantage. Table 3-11 and Table 3-12 showed that these functions include 
aforementioned proteases, antigen/antibody binding, cytokine, hormone, growth factor and ion channel 
activity. Besides many shared functions, SSA seemed to miss more functions when both CNAD and SSA 
were compared to CRC. The additional functions which were present in CRC but not in SSA include 
acetylcholine receptor, protein kinase activity and small GTPase regulator. Colorectal cancer cells have 
been known to release acetylcholine in a autocrine manner to stimulate growth (Cheng et al., 2008). A 
subcategory of acetylcholine receptors, muscarinic cholinergic receptors, have been demonstrated to 
transactivate EGFR and induce proliferation (Cheng et al., 2003). As for protein kinase activity, protein 
kinase D is a therapeutic target for CRC (Wei et al., 2014). And several small GTPase have been 
associated with colorectal cancers like RASAL1 (Ohta et al., 2009, p. 1), KRAS (Liu et al., 2011), Ral 
(Martin et al., 2011).  
 Previous transcriptome scale studies on adenomas were summarized in Table 3-14 in reverse 
chronological order. Among the studies, two employed RNA sequencing while the others were carried 
out with microarray technology. One of these studies involved a unique type of polyps: cancer adjacent 
polyp (CAP) which were polyps located within the CRC. CAP was assumed to be the origin of 
associated CRC, and considered a valuable source to study the transition from adenoma to CRC. In 
contrast to CAP, other studies including ours focused on cancer free polyp (CFP) which were polyps 
found without concurrent CRC. By comparing CAP and CFP, the author found 2452 DEGs, and these 
DEGs were overrepresented with biological processes and pathways including protein digestion, 
extracellular matrix (ECM) receptor interaction, cell cycle and p53 signaling (Druliner et al., 2018). 
Another study compared low grade intraepithelial neoplasia (LIN) and high grade intraepithelial 
neoplasia (HIN), these classifications were similar to the NAD and ADV but were based on different 
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pathological criteria. LIN refers to lesions with mild and moderate dysplasia while HIN refers to lesions 
with severe dysplasia or adenocarcinoma in situ (Lanza et al., 2011). In the comparison between HIN 
and CRC, the author reported 235 DEGs, and pooling their sequencing results together with publicly  
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Table 3-14. Summary of prior transcriptome studies on adenomas 
Study Sample Technology Design and major findings Comparison Overrepresented pathways 
Druliner et 
al., 2018 
16 CAP, 15 
CFP patients 
Whole 
transcriptome 
sequencing 
CAP gene expression is closer to paired CRC 
than CFPs. DEGs between CAPs and CFPs 
included GREM1, IGF2, CTGF, and PLAU, 
FES and HES1. ERBB3 and E2F8 only altered 
in CAPs 
CAP vs. CFP Protein digestion and 
absorption, ECM-receptor 
interaction, cell cycle and p53 
signaling pathway. 
Kanth et al., 
2016 
21 SSA, 10 
HP, 20 NAT 
Whole 
transcriptome 
sequencing 
A 51-gene panel might identify TCGA CRC 
originated from SSA. A 7-gene panel might be 
able to identify BRAF mutant, CIMP-H and 
MLH1 silenced CRC 
SSA vs. NAT NA  
HP vs. NAT NA 
Li et al., 
2015 
12 NML, 85 
LIN, 42 HIN, 
66 CRC 
microarray Upregulated DEGs from the current cohort were 
associated with survival. Sequenced and 
downloaded data yielded DEGs enriched in 
extracellular structure organization, skeletal 
system development, biological adhesion and 
itself regulated growth regulation 
HIN vs. CRC NA 
Delker et al., 
2014 
7 pairs of 
SSA and 
NAT 
Whole 
transcriptome 
sequencing 
SSA exclusive DEGs were enriched in mucosal 
integrity, cell adhesion and epithelial cell 
development 
SSA vs. NAT NA  
Pesson et al., 
2014 
37 AD, 9 
CRCs, 9 
NAT 
microarray 40-gene panel were shared among the 3 lists. AD vs. NAT Coagulation, cytokine, 
chemokine, p53 signaling, 
nitrogen metabolism 
CRC vs. 
NAT 
Cell cycle, DNA replication, 
p53 signaling, nitrogen 
metabolism 
Trend Focal adhesion, ECM, TGF-B 
signaling 
Løvf et al., 
2014 
2 CRC, 
2NAT 
Whole 
transcriptome 
sequencing 
novel lesion-specific transcript VNN1-AB 
discovered and PCR validation in 251 CRC, 6 
AD, 43 NAT 
CRC vs. 
NAT 
 
microarray AD vs. NML NA 
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Mikula et al., 
2011 
4 NAT, 12 
AD, 5 CRC* 
Validate findings using PCR in 24 NML, 42 
AD, 26 CRC. Trend identified for COL12A1, 
CALU, BGN, MAOA, ENTPD5, and MOSC2 
CRC vs. 
NML 
NA 
AD vs. CRC NA 
Trend NA 
Sabates-
Bellver et al., 
2007 
32 pairs of 
AD and NAT 
microarray Wnt targets correlated with KIAA1199 AD vs. NAT Mitosis, DNA replication, and 
spindle organization, host 
immune defense, inorganic 
anion transport, organ 
development, and inflammatory 
response 
Habermann 
et al., 2006 
3 NAT, 8 
ADs, 15 
CRC and 7 
MET 
microarray Major pathways affected: Apoptosis signaling, 
B cell receptor signaling, Cell cycle: G1/S 
checkpoint regulation, Cell cycle: G2/M DNA 
damage checkpoint, Death receptor signaling, 
ERK/MAPK signaling, Estrogen receptor 
signaling, Fatty acid metabolism, Fructose and 
mannose metabolism, G‐protein‐coupled 
receptor signaling, IL‐6 signaling, Integrin 
signaling, NF‐kB signaling, PI3/AKT signaling, 
PPAR signaling, Purine metabolism, 
SAPK/JNK signaling, Starch and sucrose 
metabolism, T cell receptor signaling, VEGF 
signaling. 
downregulation of EGFR, FOS, JUN, TGFBR2, 
APC, CDKN1A, PPID,EPHB2 
upregulation of MYC,CTNNB1, 
HIF1,HRG,EPHA7, EPHB2, CD44, MYB, and 
SLC12A2 
NAT vs. AD NA 
AD vs. CRC NA 
CRC vs. 
MET 
NA 
*pooled for each group. AD: general reference to colorectal adenomas regardless pathological or clinical classification. CAP: cancer 
adjacent polyp. CFP: cancer-free polyp. HIN: high-grade intraepithelial neoplasia. LIN: low-grade intraepithelial neoplasia. MET: 
metastasis. NAT: normal adjacent tissue from patients with AD or CRC. NML: normal colorectal mucosa from healthy people 
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available datasets produced more DEGs that were enriched with extracellular structure organization, 
biological adhesion and skeletal system development (Li et al., 2015). Another group on 2014 employed 
a design similar to ours and compared malignant and premalignant lesion with their normal counterparts 
from the same patient (Pesson et al., 2014). In their analysis, the DEGs of adenoma when contrasted to 
NAT were overrepresented with coagulation, cytokine, chemokine, p53 signaling, and nitrogen 
metabolism. Their analysis on CRC and NAT found DEGs associated with Cell cycle, DNA replication, 
p53 signaling. These results were concordant with ours except for nitrogen metabolism. They looked for 
genes with a consistent trend from NAT, adenoma to CRC, and found DEGs enriched in focal adhesion, 
ECM and TGF-β signaling. Sabates-Bellver et al. investigated the difference between adenomas and 
NAT. Their report identified DEGs related to cell division, anion transport, immune defense and 
inflammatory response. Habermann et al. discovered pathways associated with a couple domains: 
apoptosis, immune, hormone, nutrient metabolism, adhesion signaling and angiogenesis (Habermann et 
al., 2007). Finally, Kanth et al. published the only report focused on SSA among these studies (Kanth et 
al., 2016). Their investigation suggested a distinct panel of DEGs which might be a signature for SSA-
originated CRC. 
Several of these studies reported biological functions we found in our cohort, yet we were able to 
pinpoint additional pathways because of higher throughput and larger sample size. The diversity of 
adenoma subtypes were another advantage we had. Because of the samples we had access to, we were 
able to compare DEGs among clinically relevant classification (NAD and ADV) to locate pathways and 
molecular functions of importance. Finally, we were able to provide insights in the transcriptome of SSA 
which is currently understudied.  
 In conclusion, the newly discovered DEGs in ADV, NAD, CNAD and SSA delineated the 
diversity in premalignant colorectal adenomas. The discovery of tissue-specific DEGs not only serves 
hints for underlying pathophysiology, but also can be developed into biomarkers. For instance, protein 
level of serine protease in interstitial fluid or serum have been indicated to be associated with colorectal 
cancer progression (Xie et al., 2016). At last, our discovery of ‘missing pieces’ which differentiates SSA 
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or CNAD from CRC marks potential targets for the design of preventive agents which could inhibit or 
reverse the progression of adenomas.  
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4. Circulating miRNA as a Prognostic Biomarker in Non-muscle Invasive 
Bladder Cancer 
4.1 Introduction 
With 81,190 estimated new cases in 2018, bladder cancer is the 8th most incident cancer in the 
U.S (Siegel et al., 2018). About 80% of patients diagnosed with bladder cancer had lesions which have 
not invaded the muscle layer, and these lesion were referred to as non-muscle-invasive bladder cancer 
(NMIBC) (Pasin et al., 2008). Recurrence in NMIBC is extremely common. Patients who were merely 
treated with transurethral resection (TUR) had a recurrence rate of 60% 3 years after surgery (Lutzeyer et 
al., 1982). In 1976, Bacillus Calmette-guerin (BCG) was reported to be a potential treatment for NMIBC 
(Morales et al., 1976). Many later studies confirmed the efficacy of BCG, and BCG gradually became 
the standard treatment for NMIBC. A study published in 2000 followed 70 BCG-treated NMIBC patients 
for 17-134 months and found that only 17.1% recurred and 11.4% progressed (Losa et al., 2000). Despite 
the significant improvement in recurrence and progression, BCG is not without caveats. According to 
EORTC trials, about 20% of patients withdrew from full BCG treatment procedure due to systemic or 
local side effects (van der Meijden et al., 2003). In addition, a study indicated that 38.6% BCG-treated 
patients were diagnosed with recurrence within 26 months (Böhle et al., 2003).  
Many demographic and clinical factors have been demonstrated to have prognostic value. A 
report based on European Organization for Research and Treatment of Cancer (EORTC) trials proposed 
six factors: T stage, carcinoma in situ (CIS), grade, tumor size, recurrence rate and number of tumors 
(Sylvester et al., 2006). Another model using the Spanish Urological Club for Oncological Treatment 
(CUETO) trials suggested using gender, age, prior recurrence, number of tumors, T stage, associated CIS 
and grade as predictors (Fernandez-Gomez et al., 2009). However, later evaluation of the performance 
for both prediction models showed that they lack sufficient power to discriminate patients with poor and 
favorable outcomes (Xylinas et al., 2013). Therefore, exploring novel biomarkers with prognostic 
potential is a field of active study. 
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Circulating biomarkers have shown potential for clinical utility in recent years with a couple 
advantages including but not limiting to lower invasiveness, reflection of overall health and immune 
response to tumors and possibility of repeated collection. These advantages made circulating biomarkers 
an excellent candidate for screening and risk stratification. Proposed circulating biomarkers fall into the 
following categories: cell-, DNA-, methylation-, RNA- and protein-based (Nandagopal and Sonpavde, 
n.d.). Among these biomarkers, miRNA appeared to be a good candidate because of stability and ease of 
detection(Chen et al., 2008; Mitchell et al., 2008). microRNAs (miRNAs) were a group of small RNA 
molecules with length around 22 base pairs, and they were first discovered in 1993 (Lee et al., 1993) in 
c. elegans. The major physiological function of microRNA is to negatively modulate gene expression by 
binding to the 3’UTR of mRNA. The binding results in either degradation of the mRNA or prevention of 
translation (Krol et al., 2010). Prior studies have shown that circulating microRNA was associated with 
overall survival in muscle-invasive bladder cancer (MIBC) (Jiang et al., 2016), recurrence in NMIBC 
(Jiang et al., 2015) and risk of NMIBC (Lian et al., 2018). 
In the current study, we tried to identify circulating miRNAs which can be used alone or in 
combination with demographics/clinical factors in risk stratification of NMIBC. Since BCG treatment 
differs from TUR in terms of immune response (Redelman-Sidi et al., 2014) which could be reflected in 
miRNA expression, we performed stratified analysis for patients with or without BCG treatment. 
 
4.2 Methods 
4.2.1 Study population and clinical pathological data 
Subjects of this study included 290 NMIBC patients who were newly diagnosed with NMIBC 
but never received chemotherapy or radiation therapy when recruited in the MD Anderson Cancer Center 
and Baylor College of Medicine from 2002 to 2010. After receiving consent from subjects, blood sample 
was collected and injected into serum separation tubes which contains silica and polymer gel prior to 
treatment, and questionnaire on demographics along with known risk factors were administered by 
trained interviewers. During interview, family cancer history, smoking history, medical history, ethnicity 
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and race were recorded. Smoking status was categorized into never, former and current smokers. 
Subjects who smoked less than 100 cigarettes in the past were considered never smokers, and those who 
stopped smoking for more than 1 year before diagnosis were designated as former smokers. Serum was 
transferred from serum separation tubes within 2 hours and stored in liquid nitrogen until being assayed. 
We reviewed medical charts to obtain information on tumor size, stage, grade, diagnosis, treatment, date 
of diagnosis, date of recurrence, date of progression and last followup. The median followup period was 
24.3 months (95% CI: 18.8-26.0). No limitation on ethnicity was enforced during recruitment, yet the 
subjects screened for miRNA expression were limited to Caucasian because more than 90% of our 
cohort were of such ethnicity. The study protocol was reviewed and approved by the Institutional Review 
Boards of both MD Anderson Cancer Center and Baylor College of Medicine. 
4.2.2 RNA isolation, quality control and screening 
 Synthetic cel-miR-39 was added to serum before miRNA extraction, and miRNA was isolated 
with miRNeasy Mini kit (Qiagen, CA, USA). In brief, QIAzol lysis reagent was mixed with serum and 
synthetic cel-miR-39 which acted as spike-in control. Add chloroform, shake and centrifuge to obtain the 
aqueous phase. Centrifuge the aqueous phase in RNeasy mini spin column, wash and elute with RNase-
free water. Extracted RNA was stored in -80ºC until further use. Quality control steps were performed as 
described previously (Lian et al., 2018) to ensure hemolysis did not occur. TaqMan® Array Human 
MicroRNA Card Set v3.0 (Applied Biosystems, CA, USA) was employed to screen 754 miRNAs across 
10 subjects using 7900HT realtime PCR system (Applied Biosystems, CA, USA). First, stored RNA 
along with synthetic cel-miR-39 were warmed and mixed with Megaplex™ reverse transcription (RT) 
primers, dNTP with dTTP, MultiScribe™ Reverse transcriptase, RT buffer, magnesium chloride, RNase 
inhibitor and nuclease-free water (All from Applied Biosystems, CA, USA) in microcentrifuge tubes. 
Mix well, seal the tubes, spin briefly and sit on ice for 5 minutes. Run the reverse transcription in 
7900HT according to thermal cycling conditions by manufacturer: 2 min at 16ºC, 1 min at 42 ºC, 1 sec at 
50 ºC for 40 cycles followed by 5 min 85 ºC and then hold at 4 ºC until next step. Take the RT product 
and mix it with TaqMan® PreAmp Master Mix, Megaplex™ PreAmp Primers and nuclease-free water. 
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Mix well, seal, quick spin and incubate on ice for 5 mins. Run the pre-amplification step based on the 
following conditions: 10 min at 95 ºC, 2 min at 55 ºC, 2 min at 72 ºC, 12 cycles of 15 sec at 95 ºC and 4 
min at 60 ºC, 10 min at 99.9 ºC and hold at 4 ºC. Add TaqMan Universal PCR Master Mix and nuclease-
free water to pre-amplification products, mix well, seal and centrifuge shortly. Run the realtime PCR 
using the default protocol for TaqMan Low Density Arrays: 2 min at 50 ºC, 10 min at 95 ºC, and 40 
cycles of 15 sec at 95 ºC followed by 1 min at 60ºC. 89 miRNAs detected in more than 75% of samples 
with Ct value < 35 cycles and targeted cancer-related pathways were chosen as candidates for discovery 
and validation phases. In the discovery and validation phases, expression of candidate miRNAs were 
measured using realtime PCR on Fluidigm 96.96 Dynamic Array IFC and BioMark for Gene Expression 
(Fluidigm, CA, USA) in accordance with prior methodologies (Lian et al., 2018).  
4.2.3 Statistical and Pathway analysis 
ΔΔCt method for relative quantification was employed to estimate miRNA expression level. We 
first exported the Ct value for each miR and cel-miR-39 in each sample from 9700HT and BioMark. The 
expression of each miRNA was calculated using the following formulas: 
𝛥𝐶𝑇,𝑞 =  𝐶𝑇,𝑞 − 𝐶𝑇,𝑅 
𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−(∆𝐶𝑇,𝑞−Δ𝐶𝑇,𝑐𝑏 ) 
Where CT,q is the CT value for a particular miR in a particular sample q and CT,R is the arithmetic mean of 
CT values across all samples for that particular miR. And ΔCT,q denotes the difference between a 
particular miR in sample q and the mean across all samples. Finally, ΔCT,cb denotes the difference 
between Ct value for cel-miR-39 in sample q and mean of all samples. miRNA ratio risk scores (MRRSs) 
were constructed using these miRNA ratios by themselves or in combination according to whether each 
ratio was higher or lower than median. And the best MRRSs were based on two factors: 1) number of 
patients where such miRNA ratio can be measured, 2) improvement in predicting clinical outcome 
(AUC). 
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Endpoints in this study was recurrence-free survival and progression-free survival, and we 
censored samples at 5 year followup. Recurrence was defined as discovery of new NMIBC if the 
previous cystoscopy did not find any lesion. Progression was defined as discovery of muscle-invasive 
bladder cancer (higher than T2 stage) or T1 stage with high grade dysplasia which lead to cystectomy. 
Date to recurrence and date to progression was calculated by subtracting date of TUR from date of 
recurrence and date of progression. Patients without recurrence or progression were censored at last 
followup. Cox proportional hazard model was used to assess the association of miRNA ratio with the 
risk of recurrence and progression while adjusting for age at diagnosis, gender, smoking status, CIS, 
tumor size, T stage, grade and treatment. Due to the large number of miRNA ratio candidates, we 
designed a strategy to select miRNA ratios suitable for integrating into a risk score. First we calculated 
pairwise Spearman’s correlation coefficient (ρ) among candidates. For each miR ratio, we calculated the 
number of partners with absolute value of ρ larger than an arbitrarily-determined threshold (we used 0.5 
in the current study) and the average of absolute value of ρ. The miR ratio with highest number of highly 
correlated partners would be left untouched while its partners removed from the matrix. If two or more 
miR ratios had the same number of highly correlated partners, the one with higher average of absolute 
value of ρ would prevail. The process was performed until none of the candidates had highly correlated 
partners. The threshold used in this publication was 0.5. After the aforementioned selection process, the 
remaining miR ratios were used to construct risk scores. We first calculate the median of each ratio in the 
combination of discovery and validation phase, and dichotomized each ratio in both phases. We defined 
risk score as a weighted sum of the number of miR ratios which were higher than the median value in 
discovery phase. COX proportional hazard model was employed to estimate the impact of risk scores on 
clinical outcomes under multivariate situations while adjusting for age at diagnosis, sex, smoking status, 
tumor size, stage, grade and treatment. And Logrank test was performed to identify difference in 
recurrence-free and progression-free survival time among patients with higher than median risk scores 
and those with lower than median risk scores.  
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Non-parametric correlation, COX regression, Logrank test and receiver operating characteristic 
(ROC) analysis were performed in STATA 10 (StataCorp, TX, USA). Difference among continuous 
variables between groups were evaluated using Pearson X2 test, Fisher exact test, or Student’s t test. The 
selection of miR ratio candidates were implemented in R (R core team, Austria).  Targets for miRNAs 
involved in risk scores and pathways enriched with these targets were predicted using miRSystem (Lu et 
al., 2012).  
 
4.3 Results 
4.3.1 Patient Characteristics 
The current study enrolled 280 patients with NMIBC.  Of the 280 patients, 247 (88.2%) were 
male, and carcinoma in situ (Cis) was diagnosed in 144 (51.4%). 122 (43.6%) were T0a, 10 (3.6%) were 
T0is and 23 (8.2%) were T1. High grade dysplasia was confirmed in 179 (63.9%). Among BCG-treated 
patients, 129 (87.8%) were male, and cis was found in 67 (45.6%). 56 (38.1%) of the tumors were T0a, 5 
(3.4%) were T0is and 84 (57.1%) were T1. High grade dysplasia was diagnosed in 114 (77.6%). 
Treatment plans were categorized into four groups: TUR only (TUR, n = 78), TUR + induction BCG 
(iBCG, n = 73), TUR + induction BCG + maintenance BCG (mBCG, n = 74) and other (n = 55). Among 
the enrollees, recurrence was observed in 134 and progression observed in 54 within 5 years. We 
randomized our cohort into discovery and validation groups among overall and BCG-treated patients in 
order to identify miRNA expression which could be used to predict clinical outcome. The detailed 
characteristics of overall and BCG-treated groups along with recurrence and progression status is shown 
in Table 4-1 through Table 4-4. For overall recurrence, treatment was significantly associated with 
recurrence in both discovery and validation (p = 2.77x10-6 and 0.002) while T stage was borderline 
significant in discovery (p = 0.034). As for overall progression, treatment remained significantly 
different among progression and non-progression groups in both discovery and validation (p = 5.56x10-4 
and 0.007). Patients diagnosed with progressed tumors were more likely to have high grade dysplasia in  
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Table 4-1. Association between recurrence, clinical and demographic characteristics in NMIBC 
patients. 
 Discovery  Validation 
 
No recur 
n (%) 
Recur 
n (%) 
p*  
No recur 
n (%) 
Recur 
n (%) 
p* 
Age at diagnosis 
mean (SD) 62.73 (11.54) 65.40 ( 9.87) 0.149 
 
66.12 (10.05) 64.61 (11.89) 0.419 
Pack year 
mean (SD) 33.92 (30.51) 37.54 (24.48) 0.509 
 
42.82 (37.35) 40.71 (28.16) 0.759 
Sex 
   
    
Male 64 (83.12) 57 (90.48) 
 
 62 (89.86) 64 (90.14)  
Female 13 (16.88) 6 (9.52) 0.206  7 (10.14) 7 (9.86) 0.955 
Smoking status 
   
    
Never 19 (24.68) 14 (22.22) 
 
 25 (36.23) 22 (30.99)  
Former 40 (51.95) 39 (61.90) 
 
 32 (46.38) 33 (46.48)  
Current 18 (23.38) 10 (15.87) 0.433  12 (17.39) 16 (22.54) 0.687 
Cisa 
   
    
Present 32 (44.44) 18 (32.73) 
 
 33 (50.77) 24 (40.68)  
not present 40 (55.56) 37 (67.27) 0.181  32 (49.23) 35 (59.32) 0.260 
Tumor size 
   
    
<=2cm 12 (28.57) 6 (20.69) 
 
 16 (39.02) 7 (24.14)  
2-5cm 22 (52.38) 18 (62.07) 
 
 18 (43.90) 19 (65.52)  
>5cm 8 (19.05) 5 (17.24) 0.692  7 (17.07) 3 (10.34) 0.203 
T stage 
   
    
0a 34 (44.16) 30 (50.85) 
 
 26 (37.68) 32 (47.06)  
0is 0 (0) 4 (6.78) 
 
 3 (4.35) 3 (4.41)  
1 43 (55.84) 25 (42.37) 0.034  40 (57.97) 33 (48.53) 0.526 
Grade 
   
    
low/medium 28 (36.36) 21 (36.84) 
 
 19 (28.36) 20 (30.30)  
High 49 (63.64) 36 (63.16) 0.955  48 (71.64) 46 (69.70) 0.805 
Treatment 
   
    
TURb 19 (24.68) 20 (31.75) 
 
 15 (21.74) 24 (33.80)  
iBCGc 9 (11.69) 28 (44.44) 
 
 11 (15.94) 25 (35.21)  
mBCGd 31 (40.26) 6 (9.52) 
 
 24 (34.78) 13 (18.31)  
Other 18 (23.38) 9 (14.29) 2.77x10-6  19 (27.54) 9 (12.68) 0.002 
*: Student’s t-test for continuous variables. Pearson’s X2 or Fisher exact test for categorical variables. 
aCis: carcinoma in situ. bTUR: transurethral resection. ciBCG: TUR followed by induction BCG. 
dmBCG: TUR followed by iBCG and maintenance BCG.  
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Table 4-2. Association between progression, clinical and demographic characteristics in 
NMIBC patients. 
 Discovery  Validation 
 
No progress 
n (%) 
Progress 
n (%) 
p*  
No Progress 
n (%) 
Progress 
n (%) 
p* 
Age at diagnosis 
mean (SD) 64.11 (11.17) 63.19 ( 9.64) 0.694 
 
65.58 (10.84) 64.37 (11.85) 0.609 
Pack year 
mean (SD) 33.50 (28.41) 43.42 (24.62) 0.138 
 
42.10 (33.94) 40.23 (28.04) 0.826 
Sex 
   
    
Male 96 (84.96) 25 (92.59) 
 
 101 (89.38) 25 (92.59)  
Female 17 (15.04) 2 (7.41) 0.298  12 (10.62) 2 (7.41) 0.617 
Smoking status 
   
    
Never 28 (24.78) 5 (18.52) 
 
 39 (34.51) 8 (29.63)  
Former 65 (57.52) 14 (51.85) 
 
 53 (46.90) 12 (44.44)  
Current 20 (17.70) 8 (29.63) 0.361  21 (18.58) 7 (25.93) 0.680 
Cisa 
   
    
Present 41 (39.05) 9 (40.91) 
 
 48 (46.60) 9 (42.86)  
not present 64 (60.95) 13 (59.09) 0.871  55 (53.40) 12 (57.14) 0.754 
Tumor size 
   
    
<=2cm 16 (28.07) 2 (14.29) 
 
 18 (29.51) 5 (55.56)  
2-5cm 32 (56.14) 8 (57.14) 
 
 33 (54.10) 4 (44.44)  
>5cm 9 (15.79) 4 (28.57) 0.397  10 (16.39) 0 (0) 0.199 
T stage 
   
    
0a 52 (46.85) 12 (48.00) 
 
 50 (44.64) 8 (32.00)  
0is 4 (3.60) 0 (0) 
 
 6 (5.36) 0 (0)  
1 55 (49.55) 13 (52.00) 0.628  56 (50.00) 17 (68.00) 0.187 
Grade 
   
    
low/medium 41 (37.61) 8 (32.00) 
 
 37 (34.26) 2 (8.00)  
High 68 (62.39) 17 (68.00) 0.599  71 (65.74) 23 (92.00) 0.009 
Treatment 
   
    
TURb 35 (30.97) 4 (14.81) 
 
 34 (30.09) 5 (18.52)  
iBCGc 22 (19.47) 15 (55.56) 
 
 22 (19.47) 14 (51.85)  
mBCGd 35 (30.97) 2 (7.41) 
 
 32 (28.32) 5 (18.52)  
Other 21 (18.58) 6 (22.22) 5.56x10-4  25 (22.12) 3 (11.11) 0.007 
*: Student’s t-test for continuous variables. Pearson’s X2 or Fisher exact test for categorical variables. 
aCis: carcinoma in situ. bTUR: transurethral resection. ciBCG: TUR followed by induction BCG. 
dmBCG: TUR followed by iBCG and maintenance BCG. 
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Table 4-3. Association between recurrence, clinical and demographic characteristics in BCG-
treated NMIBC patients. 
 Discovery  Validation 
 
No recur 
n (%) 
Recur 
n (%) 
p*  
No recur 
n (%) 
Recur 
n (%) 
p* 
Age at diagnosis 
mean (SD) 64.03 (10.60) 65.32 (10.26) 0.596 
 
65.31 ( 9.19) 66.21 ( 9.91) 0.691 
Pack year 
mean (SD) 31.94 (27.96) 40.29 (28.08) 0.254 
 
34.31 (34.86) 39.05 (30.52) 0.614 
Sex 
   
    
Male 31 (77.50) 32 (94.12) 
 
 33 (94.29) 33 (86.84)  
Female 9 (22.50) 2 (5.88) 0.045  2 (5.71) 5 (13.16) 0.281 
Smoking status 
   
    
Never 9 (22.50) 5 (14.71) 
 
 13 (37.14) 11 (28.95)  
Former 21 (52.50) 23 (67.65) 
 
 17 (48.57) 21 (55.26)  
Current 10 (25.00) 6 (17.65) 0.415  5 (14.29) 6 (15.79) 0.757 
Cisa 
   
    
Present 19 (51.35) 14 (46.67) 
 
 17 (51.52) 17 (50.00)  
not present 18 (48.65) 16 (53.33) 0.703  16 (48.48) 17 (50.00) 0.901 
Tumor size 
   
    
<=2cm 6 (28.57) 5 (33.33) 
 
 9 (42.86) 5 (31.25)  
2-5cm 11 (52.38) 7 (46.67) 
 
 10 (47.62) 9 (56.25)  
>5cm 4 (19.05) 3 (20.00) 0.939  2 (9.52) 2 (12.50) 0.767 
T stage 
   
    
0a 16 (40.00) 13 (39.39) 
 
 13 (37.14) 14 (37.84)  
0is 0 (0) 3 (9.09) 
 
 1 (2.86) 1 (2.70)  
1 24 (60.00) 17 (51.52) 0.144  21 (60.00) 22 (59.46) 0.998 
Grade 
   
    
low/medium 11 (27.50) 5 (16.13) 
 
 6 (17.14) 6 (16.67)  
High 29 (72.50) 26 (83.87) 0.255  29 (82.86) 30 (83.33) 0.957 
Treatment 
   
    
iBCGb 9 (22.50) 28 (82.35) 
 
 11 (31.43) 25 (65.79)  
mBCGc 31 (77.50) 6 (17.65) 2.87x10-7  24 (68.57) 13 (34.21) 0.003 
*: Student’s t-test for continuous variables. Pearson’s X2 or Fisher exact test for categorical variables. 
aCis: carcinoma in situ. biBCG: TUR followed by induction BCG. cmBCG: TUR followed by iBCG and 
maintenance BCG. 
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Table 4-4. Association between progression, clinical and demographic characteristics in BCG-
treated NMIBC patients. 
 Discovery  Validation 
 
No progress 
n (%) 
Progress 
n (%) 
p*  
No Progress 
n (%) 
Progress 
n (%) 
p* 
Age at diagnosis 
mean (SD) 64.53 (10.81) 64.94 ( 9.13) 0.886 
 
65.61 ( 9.58) 66.26 ( 9.59) 0.799 
Pack year 
mean (SD) 32.72 (28.37) 46.70 (25.23) 0.104 
 
35.82 (34.54) 39.35 (27.18) 0.734 
Sex 
   
    
Male 47 (82.46) 16 (94.12) 
 
 49 (90.74) 17 (89.47)  
Female 10 (17.54) 1 (5.88) 0.236  5 (9.26) 2 (10.53) 0.872 
Smoking status 
   
    
Never 11 (19.30) 3 (17.65) 
 
 19 (35.19) 5 (26.32)  
Former 34 (59.65) 10 (58.82) 
 
 28 (51.85) 10 (52.63)  
Current 12 (21.05) 4 (23.53) 0.972  7 (12.96) 4 (21.05) 0.622 
Cisa 
   
    
Present 26 (49.06) 7 (50.00) 
 
 27 (51.92) 7 (46.67)  
not present 27 (50.94) 7 (50.00) 0.950  25 (48.08) 8 (53.33) 0.720 
Tumor size 
   
    
<=2cm 9 (32.14) 2 (25.00) 
 
 10 (33.33) 4 (57.14)  
2-5cm 13 (46.43) 5 (62.50) 
 
 16 (53.33) 3 (42.86)  
>5cm 6 (21.43) 1 (12.50) 0.712  4 (13.33) 0 (0) 0.386 
T stage 
   
    
0a 21 (37.50) 8 (47.06) 
 
 23 (42.59) 4 (22.22)  
0is 3 (5.36) 0 
 
 2 (3.70) 0 (0)  
1 32 (57.14) 9 (52.94) 0.535  29 (53.70) 14 (77.78) 0.176 
Grade 
   
    
low/medium 13 (23.64) 3 (18.75) 
 
 11 (20.75) 1 (5.56)  
High 42 (76.36) 13 (81.25) 0.681  42 (79.25) 17 (94.44) 0.137 
Treatment 
   
    
iBCGb 22 (38.60) 15 (88.24) 
 
 22 (40.74) 14 (73.68)  
mBCGc 35 (61.40) 2 (11.76) 3.28x10-4  32 (59.26) 5 (26.32) 0.013 
*: Student’s t-test for continuous variables. Pearson’s X2 or Fisher exact test for categorical variables. 
aCis: carcinoma in situ. biBCG: TUR followed by induction BCG. cmBCG: TUR followed by iBCG and 
maintenance BCG. 
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their prior tumor in validation (p = 0.009) in validation but not discovery. Recurrence in BCG-treated 
patients was highly associated with treatment in both discovery and validation where patients with 
recurrence were less likely to have received mBCG (p = 2.87x10-7 and 0.003). Difference in sex among 
progression and non-progression patients was borderline significant in discovery (p = 0.045) but not 
validation. A similar association between treatment and progression was observed in both discovery and 
validation (p = 3.28x10-4 and 0.013). In summary, patients with recurrence and progression of bladder 
cancer are less likely to have been treated with mBCG. 
4.3.2 Identification of miRNA Ratios and Construction of Risk Scores Predictive of 
Recurrence and Progression 
After obtaining the miRNA expression, the ratio of each pair of miRNA in the discovery phase 
and validation phase was calculated. And miRNA ratios were selected based on 2 criteria: 1) no evidence 
of being different between discovery phase and validation phase based on the Wilcoxon Rank Sum test 
and 2) detectable in more than 75% of samples. These criteria resulted in 1587 and 1471 miRNA ratio 
candidates in overall and BCG cohort for further examination.  
To identify miRNA ratios associated with recurrence and progression in overall population, we 
calculated the hazard ratio of candidate miRNA ratios. There were 114 and 520 miRNA ratios associated 
with recurrence and progression in discovery phase of overall population. Among the 114 ratios 
associated with recurrence, 6 were validated in validation phase. And 190 out of 520 progression-related 
miRNA ratios were validated. We further constructed a risk score based on different combinations of 
validated miRNA ratios to provide a better stratification of patient risk as detailed in Material and 
Methods. After the aforementioned selection process, 3 (miR-24/miR-152, miR-25/miR-191, miR-
130a/miR-409-3p) and 14 miR ratios (miR-152/miR-423-5p, miR-221/miR-376a, miR-16/miR-378, 
miR-19b/miR-30d, miR-18/miR-30b, miR-21/miR-151-3p, miR-24/miR-125b, miR-24/miR-331-3p, 
miR-25/miR-1274b, miR-106b/miR-150, miR-92a/miR-484, miR-155/miR-186, miR-375/miR-532-3p, 
miR-532-3p/miR-486-5p) remained. The effect of individual miR on recurrence and progression is 
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shown in Table 4-5 and Table 4-6Error! Reference source not found.. Based on the selection criteria 
described in Materials and  
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Table 4-5. Association between microRNA ratio candidates and recurrence in overall population 
  Discovery  Validation  Combined 
  Event (%) No Event (%) HR* (95% CI) p value  Event (%) No Event (%) HR* (95% CI) p value  Event (%) No Event (%) HR* (95% CI) p value 
miR-24/miR-152 Low 29 (50.9) 28 (49.1) 1 (reference)  
 
28 (53.8) 24 (46.2) 1 (reference)   57 (52.3) 52 (47.7) 1 (reference)  
  High 24 (42.1) 33 (57.9) 0.51 (0.27-0.95) 0.034 
 
28 (46.7) 32 (53.3) 0.48 (0.27-0.89) 0.019  52 (44.4) 65 (55.6) 0.56 (0.37-0.86) 0.008 
miR-25/miR-191 Low 22 (36.7) 38 (63.3) 1 (reference)  
 
24 (42.1) 33 (57.9) 1 (reference)   46 (39.3) 71 (60.7) 1 (reference)  
  High 31 (52.5) 28 (47.5) 2.22 (1.05-4.7) 0.037 
 
35 (58.3) 25 (41.7) 2.01 (1.09-3.7) 0.026  66 (55.5) 53 (44.5) 1.82 (1.18-2.83) 0.007 
miR-130a/miR-409-3p Low 22 (38.6) 35 (61.4) 1 (reference)  
 
32 (45.1) 39 (54.9) 1 (reference)   54 (42.2) 74 (57.8) 1 (reference)  
 
High 31 (54.4) 26 (45.6) 2.29 (1.18-4.47) 0.015 
 
25 (58.1) 18 (41.9) 2 (1.08-3.71) 0.027  56 (56) 44 (44) 2.06 (1.33-3.18) 0.001 
*: Adjusted for age at diagnosis, sex, smoking status, tumor size, stage, grade, treatment 
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Table 4-6.  Association between microRNA ratio candidates and progression in overall population 
 Discovery  Validation  Combined 
  Event (%) No Event (%) HR* (95% CI) p value  Event (%) No Event (%) HR* (95% CI) p value  Event (%) No Event (%) HR* (95% CI) p value 
miR-152/miR-423-5p Low 6 (11.1) 48 (88.9) 1 (reference)  
 
8 (13.3) 52 (86.7) 1 (reference)   14 (12.3) 100 (87.7) 1 (reference)  
 
High 12 (22.6) 41 (77.4) 10.75 (2.63-43.92) 0.001 
 
12 (25) 36 (75) 4.64 (1.47-14.65) 0.009  24 (23.8) 77 (76.2) 3.6 (1.67-7.79) 0.001 
miR-221/miR-376a Low 14 (25.9) 40 (74.1) 1 (reference)  
 
17 (27.4) 45 (72.6) 1 (reference)   31 (26.7) 85 (73.3) 1 (reference)  
 
High 5 (9.4) 48 (90.6) 0.16 (0.04-0.59) 0.006 
 
5 (9.4) 48 (90.6) 0.14 (0.04-0.48) 0.002  10 (9.4) 96 (90.6) 0.2 (0.09-0.46) 0 
miR-16/miR-378 Low 7 (11.3) 55 (88.7) 1 (reference)  
 
7 (11.5) 54 (88.5) 1 (reference)   14 (11.4) 109 (88.6) 1 (reference)  
 
High 16 (26.2) 45 (73.8) 4.17 (1.28-13.56) 0.018 
 
17 (28.3) 43 (71.7) 3.98 (1.36-11.61) 0.012  33 (27.3) 88 (72.7) 3.32 (1.64-6.7) 0.001 
miR-19b/miR-30d Low 17 (27.9) 44 (72.1) 1 (reference)   19 (29.7) 45 (70.3) 1 (reference)   36 (28.8) 89 (71.2) 1 (reference)  
 High 5 (8.3) 55 (91.7) 0.2 (0.06-0.67) 0.009  6 (10.3) 52 (89.7) 0.25 (0.1-0.67) 0.005  11 (9.3) 107 (90.7) 0.27 (0.13-0.56) 0 
miR-18/miR-30b Low 13 (24.1) 41 (75.9) 1 (reference)   18 (30) 42 (70) 1 (reference)   31 (27.2) 83 (72.8) 1 (reference)  
 High 4 (7.4) 50 (92.6) 0.12 (0.03-0.56) 0.007  8 (14) 49 (86) 0.28 (0.1-0.79) 0.016  12 (10.8) 99 (89.2) 0.29 (0.13-0.62) 0.002 
miR-21/miR-151-3p Low 16 (27.6) 42 (72.4) 1 (reference)   17 (27.4) 45 (72.6) 1 (reference)   33 (27.5) 87 (72.5) 1 (reference)  
 High 6 (10.3) 52 (89.7) 0.26 (0.08-0.81) 0.02  4 (7.5) 49 (92.5) 0.16 (0.04-0.57) 0.005  10 (9) 101 (91) 0.23 (0.1-0.51) 0 
miR-24/miR-125b Low 11 (20.4) 43 (79.6) 1 (reference)   19 (30.2) 44 (69.8) 1 (reference)   30 (25.6) 87 (74.4) 1 (reference)  
 High 8 (15.1) 45 (84.9) 0.21 (0.05-0.89) 0.034  5 (9.1) 50 (90.9) 0.25 (0.08-0.79) 0.018  13 (12) 95 (88) 0.25 (0.11-0.57) 0.001 
miR-24/miR-331-3p Low 16 (25.8) 46 (74.2) 1 (reference)   17 (27.9) 44 (72.1) 1 (reference)   33 (26.8) 90 (73.2) 1 (reference)  
 High 7 (11.3) 55 (88.7) 0.27 (0.1-0.79) 0.016  7 (11.3) 55 (88.7) 0.2 (0.07-0.56) 0.002  14 (11.3) 110 (88.7) 0.26 (0.13-0.53) 0 
miR-25/miR-1274b Low 7 (11.5) 54 (88.5) 1 (reference)   8 (11.9) 59 (88.1) 1 (reference)   15 (11.7) 113 (88.3) 1 (reference)  
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 High 16 (26.2) 45 (73.8) 2.83 (1.03-7.83) 0.044  17 (27) 46 (73) 2.95 (1.1-7.93) 0.032  33 (26.6) 91 (73.4) 2.36 (1.23-4.53) 0.01 
miR-106b/miR-150 Low 7 (12.1) 51 (87.9) 1 (reference)   6 (11.5) 46 (88.5) 1 (reference)   13 (11.8) 97 (88.2) 1 (reference)  
 High 14 (24.1) 44 (75.9) 5.97 (1.86-19.14) 0.003  18 (29) 44 (71) 3.75 (1.13-12.43) 0.031  32 (26.7) 88 (73.3) 3.13 (1.5-6.54) 0.002 
miR-92a/miR-484 Low 7 (10.9) 57 (89.1) 1 (reference)   9 (13.8) 56 (86.2) 1 (reference)   16 (12.4) 113 (87.6) 1 (reference)  
 High 14 (22.2) 49 (77.8) 5.18 (1.6-16.71) 0.006  17 (26.6) 47 (73.4) 3.39 (1.26-9.15) 0.016  31 (24.4) 96 (75.6) 3.31 (1.62-6.77) 0.001 
miR-155/miR-186 Low 10 (18.9) 43 (81.1) 1 (reference)   10 (18.5) 44 (81.5) 1 (reference)   20 (18.7) 87 (81.3) 1 (reference)  
 High 5 (9.4) 48 (90.6) 0.25 (0.06-0.98) 0.046  9 (14.3) 54 (85.7) 0.3 (0.09-0.94) 0.039  14 (12.1) 102 (87.9) 0.41 (0.19-0.92) 0.031 
miR-375/miR-532-3p Low 4 (6.8) 55 (93.2) 1 (reference)   7 (11.5) 54 (88.5) 1 (reference)   11 (9.2) 109 (90.8) 1 (reference)  
 High 16 (27.6) 42 (72.4) 14.83 (2.59-85) 0.002  15 (25.4) 44 (74.6) 5.29 (1.7-16.46) 0.004  31 (26.5) 86 (73.5) 5.92 (2.61-13.46) 0 
miR-532-3p/miR-486-5p Low 17 (30.4) 39 (69.6) 1 (reference)   17 (29.3) 41 (70.7) 1 (reference)   34 (29.8) 80 (70.2) 1 (reference)  
 High 5 (8.9) 51 (91.1) 0.22 (0.07-0.66) 0.007  7 (11.7) 53 (88.3) 0.35 (0.13-0.93) 0.036  12 (10.3) 104 (89.7) 0.28 (0.14-0.56) 0 
*: Adjusted for age at diagnosis, sex, smoking status, tumor size, stage, grade, treatment 
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Methods, we found that miR-24/miR-152 alone provided the best prediction in both discovery and 
validation phases. Using miR-24/miR-152 as MRRS along with demographic and clinical variables 
improves the prediction of recurrence by 2.7% reaching an AUC of 0.75 (Figure 4-1), and this MRRS 
can be measured in more than 80% of the patients. As for progression, miR-16/miR-378 combined with 
miR-24/miR-331-3p risk score resulted in 10.3% increase in AUC in addition to demographic and 
clinical variables, and the final AUC approached 83.6% (Figure 4-2) in more than 75% of patients. 
Using this MRRS alone performed as well as demographics combined with treatment suggesting the 
potential of replacing the traditional prognosis prediction model. Figure 4-3 showed that the 
progression-free survival curve for patients with higher and lower than median MRRS were significantly 
different (p < 0.001). 
 Similar procedures were carried out in BCG-treated patients, and we found 115 and 603 miRNA 
ratios associated with recurrence and progression in discovery phase of BCG population. 7 out 115 and 
62 out of 603 miR ratios were validated. After applying selection strategies for combination candidates, 
we were left with 2 (miR-19a/miR-484, miR-146a/miR-152) and 6 miR ratios (miR-16/miR-21, miR-
19b/miR-25, miR-30d/miR-331-3p, miR-331-3p/miR-378, miR-18/miR-376a, miR-24/hsa-miR-375) 
associated with recurrence and progression, respectively. The impact of these miR ratios on clinical 
outcomes was detailed in Table 4-7 and Table 4-8. Among these miR ratios, miR-146a/miR-152 MRRS 
combined with demographic and clinical variables was able to predict recurrence with 90.5% AUC in 
more than 80% (Figure 4-4) of patients. Finally, we found that miR-16/miR-21 and miR-24/miR-375 
MRRS alone resulted in 87.8% prediction, which outperformed the demographics and clinical feature 
model by 16.8% and can be applied to more than 72% of patients (Figure 4-5). And integration of this 
MRRS with demographics and clinical features further increased the prediction to 94.5% suggesting the 
strong potential for clinical application. The progression-free survival curve in Figure 4-6 demonstrated 
the significant difference between patients with high and low MRRS (p < 0.001). All the MRRSs found 
in BCG cohort have been validated that they were not associated with clinical outcomes in 78 TUR only 
patients (data not shown).  
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Figure 4-1. ROC curve for recurrence prediction models in overall population 
 
Black (EC): epidemiology and clinical variables including: age at diagnosis, sex, smoking 
status, tumor size, stage, grade and treatment.  Blue (MR): MRRS. Red (EC+MR): combination 
of all predictors in the two prior models. 
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Figure 4-2. ROC curves for progression prediction models in overall population 
 
Black (EC): epidemiology and clinical variables including: age at diagnosis, sex, smoking 
status, tumor size, stage, grade and treatment.  Blue (MR): MRRS. Red (EC+MR): combination 
of all predictors in the two prior models. 
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Figure 4-3. Kaplan-Meier estimates for progression-free survival in overall population 
 
Blue: lower than median MRRS. Red: higher than median MRRS. 
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Figure 4-4. ROC curves for recurrence prediction models in BCG-treated population 
 
Black (EC): epidemiology and clinical variables including: age at diagnosis, sex, smoking 
status, tumor size, stage, grade and treatment.  Blue (MR): MRRS. Red (EC+MR): combination 
of all predictors in the two prior models. 
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Figure 4-5. ROC curves for progression prediction models in BCG-treated population 
 
Black (EC): epidemiology and clinical variables including: age at diagnosis, sex, smoking 
status, tumor size, stage, grade and treatment.  Blue (MR): MRRS. Red (EC+MR): combination 
of all predictors in the two prior models. 
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Figure 4-6. Kaplan-Meier estimates for progression-free survival in overall population 
 
Blue: lower than median MRRS. Red: higher than median MRRS. 
  
104 
 
Table 4-7. Association between microRNA ratio candidates and recurrence in BCG-treated population 
  Discovery  Validation   Combined 
  Event (%) No Event (%) HR* (95% CI) p value  Event (%) No Event (%) HR* (95% CI) p value Event (%) No Event (%) HR* (95% CI) p value 
 
miR-19a/miR-484 Low 9 (30) 21 (70) 1 (reference)  
 
16 (42.1) 22 (57.9) 1 (reference)  25 (36.8) 43 (63.2) 1 (reference)   
  High 17 (54.8) 14 (45.2) 3.37 (1.2-9.48) 0.021 
 
20 (66.7) 10 (33.3) 2.43 (1.1-5.37) 0.029 37 (60.7) 24 (39.3) 2.08 (1.16-3.73) 0.013  
miR-146a/miR-152 Low 16 (51.6) 15 (48.4) 1 (reference)   17 (63) 10 (37) 1 (reference)  33 (56.9) 25 (43.1) 1 (reference)   
  High 10 (37) 17 (63) 0.34 (0.12-0.94) 0.038  11 (39.3) 17 (60.7) 0.24 (0.09-0.64) 0.004 21 (38.2) 34 (61.8) 0.47 (0.25-0.87) 0.016  
miR-320b/miR-1274b Low 15 (46.9) 17 (53.1) 1 (reference)  
 
24 (63.2) 14 (36.8) 1 (reference)  39 (55.7) 31 (44.3) 1 (reference)   
  High 12 (41.4) 17 (58.6) 0.32 (0.11-0.95) 0.041 
 
8 (40) 12 (60) 0.34 (0.12-0.97) 0.044 20 (40.8) 29 (59.2) 0.58 (0.31-1.07) 0.081  
*: Adjusted for age at diagnosis, sex, smoking status, tumor size, stage, grade, treatment 
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Table 4-8. Association between microRNA ratio candidates and progression in BCG-treated population 
  Discovery  Validation  Combined 
  Event (%) No Event (%) HR* (95% CI) p value  Event (%) No Event (%) HR* (95% CI) p value 
 
Event (%) No Event (%) HR* (95% CI) p value 
miR-16/miR-21 Low 2 (6.9) 27 (93.1) 1 (reference)  
 
3 (10) 27 (90) 1 (reference)   5 (8.5) 54 (91.5) 1 (reference)  
 
High 9 (34.6) 17 (65.4) 11.97 (1.16-123.83) 0.037 
 
10 (30.3) 23 (69.7) 8.97 (1.51-53.35) 0.016  19 (32.2) 40 (67.8) 6.69 (2.04-21.9) 0.002 
miR-19b/miR-25 Low 10 (29.4) 24 (70.6) 1 (reference)  
 
12 (29.3) 29 (70.7) 1 (reference)   22 (29.3) 53 (70.7) 1 (reference)  
 
High 3 (10) 27 (90) 0.07 (0.01-0.41) 0.003 
 
6 (21.4) 22 (78.6) 0.26 (0.08-0.85) 0.025  9 (15.5) 49 (84.5) 0.2 (0.08-0.49) 0 
miR-30d/miR-331-3p Low 3 (11.1) 24 (88.9) 1 (reference)   4 (19) 17 (81) 1 (reference)   7 (14.6) 41 (85.4) 1 (reference)  
 High 9 (29) 22 (71) 19.86 (1.88-209.93) 0.013  11 (29.7) 26 (70.3) 4.65 (1.04-20.89) 0.045  20 (29.4) 48 (70.6) 2.76 (0.99-7.7) 0.052 
miR-331-3p/miR-378 Low 3 (10) 27 (90) 1 (reference)   7 (20) 28 (80) 1 (reference)   10 (15.4) 55 (84.6) 1 (reference)  
 High 10 (29.4) 24 (70.6) 23.65 (1.87-298.38) 0.014  9 (33.3) 18 (66.7) 4.55 (1.14-18.14) 0.032  19 (31.1) 42 (68.9) 4.41 (1.71-11.37) 0.002 
miR-18/miR-376a Low 8 (25) 24 (75) 1 (reference)   15 (34.1) 29 (65.9) 1 (reference)   23 (30.3) 53 (69.7) 1 (reference)  
 High 3 (10) 27 (90) 0.02 (0-0.32) 0.005  3 (13.6) 19 (86.4) 0.26 (0.07-0.99) 0.048  6 (11.5) 46 (88.5) 0.17 (0.06-0.53) 0.002 
miR-24/hsa-miR-375 Low 10 (31.3) 22 (68.8) 1 (reference)   11 (33.3) 22 (66.7) 1 (reference)   21 (32.3) 44 (67.7) 1 (reference)  
 High 4 (11.1) 32 (88.9) 0.16 (0.03-0.74) 0.02  6 (17.6) 28 (82.4) 0.18 (0.04-0.76) 0.02  10 (14.3) 60 (85.7) 0.29 (0.12-0.67) 0.004 
*: Adjusted for age at diagnosis, sex, smoking status, tumor size, stage, grade, treatment 
  
106 
 
4.3.3 Pathways and Biological Functions of Predicted miRNA Targets 
Enrichment of target genes for MRRSs were analyzed by miRSystem. For overall recurrence 
MRRS, target genes of miR-24 and miR-152 were enriched in pathways shown in Table 4-9. Many of 
these pathways have been associated with bladder cancer outcome. For example, FOXM1, c-myc, 
Aurora-A expression have been associated with survival in muscle-invasive bladder cancer (Lei et al., 
2011; Massari et al., 2015; Rinaldetti et al., 2017). Targets of progression-associated miR-16/miR-378 
and miR-24/miR-331-3p were found significantly more often in pathways listed in Table 4-10. Several 
of these pathways (CDC42, MAPK, Glutamate receptor and focal adhesion kinase signaling) have been 
demonstrated to involve in bladder cancer pathophysiology (Kong et al., 2015; Lv et al., 2017; Mora 
Vidal et al., 2018; Volanis et al., 2011).  In addition, platelet count has been suggested to be a prognostic 
factor of bladder cancer survival (Peng et al., 2018; Wang et al., 2017). 
When we limited the analysis to patients who received BCG treatment, miR-146a and miR-152 
targets pathways listed in Table 4-11. A wide variety of these pathways were immune-related (SHP-2, 
IL-1, TCR, TLR, chemokine, RIG-I, TRAIL, NOD1, NOD2 and GMCSF signaling) (Choudhury et al., 
2016; Correa et al., 2012, p. 1; Hong, 2016; Ranoa et al., 2016; Seddighzadeh et al., 2003; Su et al., 
2007; Yu et al., 2015; Zhao et al., 2013; Zhu et al., 2016, p. 5) reflecting the close link between BCG 
treatment and immune activation. Similar to the previous panel, progression-associated miR-19b and 
miR-25 targets immune-related pathways (EPHB, CD8+ T cell, CXCR4 and Fc Epsilon signaling) as 
well as Epithelial-to-mesenchymal transition pathways (Wnt and Sonic Hedgehog) and platelet-related 
pathways (GPVI) as shown in Table 4-12. Another panel for prediction of progression (miR-16, miR-21, 
miR-24 and miR-375) also had predicted targets associated with the immune system (IL-2, IL-12, IL-23, 
IL-27, calcineurin, NKT and Fc Epsilon signaling). Interestingly, several sugar metabolism pathways 
were targeted (fructose, mannose, galactose and glycolysis) indicating the possible impact of metabolism 
in bladder cancer survival (Massari et al., 2016). 
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Table 4-9. Pathways enriched with genes targeted by recurrence-associated miRNAs (miR-24 
and miR-152) in overall population 
Database Pathway 
All Genes in 
Pathway 
Target Genes 
in Pathway 
Empirical 
p value 
PID FOXM1 Transcription Factor Network 41 12 (29.27) 1.93E-04 
KEGG Focal Adhesion 199 22 (11.06) 8.57E-04 
REA Cytokine Signaling In Immune System 220 19 (8.64) 9.01E-04 
PID ATF-2 Transcription Factor Network 58 10 (17.24) 1.09E-03 
PID Validated Targets Of c-Myc Transcriptional 
Repression 
63 9 (14.29) 1.14E-03 
KEGG Hematopoietic Cell Lineage 88 9 (10.23) 1.20E-03 
REA Translocation Of Zap-70 To Immunological 
Synapse 
29 3 (10.35) 1.44E-03 
KEGG MAPK Signaling Pathway 272 27 (9.93) 1.75E-03 
PID Presenilin Action In Notch And Wnt 
Signaling 
46 9 (19.57) 1.96E-03 
PID P73 Transcription Factor Network 73 11 (15.07) 2.12E-03 
KEGG Acute Myeloid Leukemia 57 10 (17.54) 2.71E-03 
PID TRK Receptor Signaling Mediated By The 
MAPK Pathway 
33 7 (21.21) 2.92E-03 
PID TCR Signaling In Naive CD8+ T Cells 51 9 (17.65) 3.30E-03 
KEGG Regulation Of Actin Cytoskeleton 213 19 (8.92) 3.79E-03 
PID Aurora A Signaling 31 6 (19.36) 3.90E-03 
PID SHP2 Signaling 54 8 (14.82) 3.98E-03 
PID Reelin Signaling Pathway 29 6 (20.69) 4.15E-03 
PID c-Myb Transcription Factor Network 81 11 (13.58) 4.41E-03 
KEGG Chronic Myeloid Leukemiaa 73 9 (12.33) 5.03E-03 
REA Signaling By Interleukins 106 11 (10.38) 5.09E-03 
REA Nuclear Receptor Transcription Pathway 51 7 (13.73) 5.15E-03 
KEGG T Cell Receptor Signaling Pathway 108 13 (12.04) 5.21E-03 
PID CXCR4-Mediated Signaling Events 102 11 (10.78) 5.54E-03 
PID Nectin Adhesion Pathway 28 6 (21.43) 6.00E-03 
PID Validated Nuclear Estrogen Receptor Alpha 
Network 
63 8 (12.7) 7.92E-03 
KEGG Pathways In Cancer 325 27 (8.31) 8.36E-03 
KEGG Allograft Rejection 37 5 (13.51) 8.84E-03 
KEGG Type I Diabetes Mellitus 43 7 (16.28) 9.05E-03 
KEGG Antigen Processing And Presentation 76 5 (6.58) 9.12E-03 
REA Downstream Signal Transductionb 93 11 (11.83) 9.23E-03 
KEGG Bladder Cancerc 42 7 (16.67) 9.62E-03 
PID Il2 Signaling Events Mediated By Stat5 30 5 (16.67) 1.03E-02 
KEGG Small Cell Lung Cancer 84 10 (11.91) 1.03E-02 
REA Integrin Cell Surface Interactions 85 11 (12.94) 1.04E-02 
REA Signaling By SCF-Kit 78 10 (12.82) 1.08E-02 
REA Signaling By Insulin Receptor 109 10 (9.17) 1.13E-02 
KEGG Graft-Versus-Host Disease 41 6 (14.63) 1.16E-02 
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REA Signaling By PDGF 122 15 (12.3) 1.22E-02 
REA Costimulation By The CD28 Family 77 8 (10.39) 1.23E-02 
REA IRS-Related Events 81 9 (11.11) 1.25E-02 
REA IRS-Mediated Signalling 81 9 (11.11) 1.25E-02 
REA Signalling By NGF 221 21 (9.5) 1.31E-02 
REA Downstream Signaling Of Activated FGFR 100 10 (10) 1.33E-02 
PID ARF6 Trafficking Events 49 6 (12.25) 1.39E-02 
BIOC Biocarta IL2RB Pathway 38 6 (15.79) 1.43E-02 
REA Signalling To ERKs 35 5 (14.29) 1.44E-02 
PID TCR Signaling In Naive Cd4+ T Cells 64 9 (14.06) 1.45E-02 
PID IL2-Mediated Signaling Events 54 8 (14.82) 1.46E-02 
REA GAB1 Signalosome 39 6 (15.39) 1.47E-02 
BIOC Biocarta G1 Pathway 28 5 (17.86) 1.48E-02 
KEGG Basal Transcription Factors 35 5 (14.29) 1.54E-02 
KEGG Melanoma 71 7 (9.86) 1.57E-02 
REA Interleukin-2 Signaling 42 5 (11.91) 1.58E-02 
KEGG Regulation Of Autophagy 34 4 (11.77) 1.62E-02 
KEGG Glioma 65 7 (10.77) 1.64E-02 
PID Fc-Epsilon Receptor I Signaling In Mast 
Cells 
61 9 (14.75) 1.65E-02 
PID IFN-Gamma Pathway 42 7 (16.67) 1.66E-02 
REA Interleukin-1 Signaling 40 6 (15) 1.68E-02 
REA Insulin Receptor Signalling Cascade 86 9 (10.47) 1.68E-02 
KEGG Axon Guidance 129 13 (10.08) 1.69E-02 
PID Regulation Of Telomerase 67 8 (11.94) 1.69E-02 
REA NGF Signalling Via TRKA From The 
Plasma Membrane 
136 14 (10.29) 1.74E-02 
PID Notch Signaling Pathway 59 9 (15.25) 1.74E-02 
KEGG Cytokine-Cytokine Receptor Interaction 275 18 (6.55) 1.79E-02 
PID Integrin Family Cell Surface Interactions 26 4 (15.39) 1.80E-02 
REA TCR Signaling 69 8 (11.59) 1.80E-02 
KEGG Toxoplasmosis 132 10 (7.58) 1.82E-02 
PID Beta1 Integrin Cell Surface Interactions 65 10 (15.39) 1.83E-02 
PID EphB Forward Signaling 36 7 (19.44) 1.85E-02 
REA Developmental Biology 494 34 (6.88) 1.88E-02 
PID IL23-Mediated Signaling Events 37 6 (16.22) 1.93E-02 
REA FRS2-Mediated Cascade 38 4 (10.53) 1.97E-02 
KEGG Prostate Cancer 89 11 (12.36) 2.05E-02 
KEGG Neurotrophin Signaling Pathway 127 15 (11.81) 2.06E-02 
REA PI3K Akt Activation 37 6 (16.22) 2.18E-02 
REA S Phase 112 8 (7.14) 2.20E-02 
KEGG ECM-Receptor Interaction 84 11 (13.1) 2.23E-02 
REA Signaling By Notch 25 5 (20) 2.28E-02 
PID Validated Transcriptional Targets Of TAp63 
Isoforms 
51 7 (13.73) 2.40E-02 
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KEGG Non-Small Cell Lung Cancer 54 6 (11.11) 2.47E-02 
REA Hemostasis 467 30 (6.42) 2.50E-02 
REA Metabolism Of Amino Acids And 
Derivatives 
174 1 (0.58) 2.51E-02 
REA Signaling By FGFR 114 10 (8.77) 2.52E-02 
PID IL1-Mediated Signaling Events 35 5 (14.29) 2.62E-02 
KEGG Maturity Onset Diabetes Of The Young 25 4 (16) 2.64E-02 
REA Generic Transcription Pathway 244 11 (4.51) 2.64E-02 
PID Signaling Events Mediated By Focal 
Adhesion Kinase 
58 9 (15.52) 2.74E-02 
PID IL12 Signaling Mediated By Stat4 33 5 (15.15) 2.75E-02 
REA Cyclin A CDK2-Associated Events At S 
Phase Entry 
66 6 (9.09) 2.75E-02 
KEGG Renal Cell Carcinoma 70 9 (12.86) 2.78E-02 
KEGG Natural Killer Cell Mediated Cytotoxicity 140 8 (5.71) 2.84E-02 
REA Cell Surface Interactions At The Vascular 
Wall 
94 7 (7.45) 2.84E-02 
PID Integrins In Angiogenesis 74 12 (16.22) 2.91E-02 
REA G Alpha (S) Signaling Events 125 9 (7.2) 3.00E-02 
REA Downstream TCR Signaling 52 6 (11.54) 3.07E-02 
KEGG Lysosome 121 9 (7.44) 3.10E-02 
REA Transcriptional Regulation Of White 
Adipocyte Differentiation 
69 8 (11.59) 3.13E-02 
KEGG Cell Cycle 124 12 (9.68) 3.20E-02 
REA Cell Cycle Mitotic 330 20 (6.06) 3.30E-02 
BIOC Biocarta HIV Nef Pathway 58 7 (12.07) 3.31E-02 
REA Interferon Signaling 110 7 (6.36) 3.40E-02 
PID AMB2 Integrin Signaling 41 5 (12.2) 3.43E-02 
REA Interferon Gamma Signaling 73 6 (8.22) 3.51E-02 
KEGG Dilated Cardiomyopathy 90 8 (8.89) 3.52E-02 
KEGG B Cell Receptor Signaling Pathway 75 7 (9.33) 3.54E-02 
PID E2F Transcription Factor Network 73 10 (13.7) 3.55E-02 
REA Metabolism Of Water-Soluble Vitamins And 
Cofactors 
51 4 (7.84) 3.65E-02 
REA Metabolism Of Vitamins And Cofactors 51 4 (7.84) 3.65E-02 
PID FOXO Family Signaling 49 8 (16.33) 3.75E-02 
PID Downstream Signaling In Naive CD8+ T 
Cells 
68 7 (10.29) 3.76E-02 
REA G Alpha (I) Signalling Events 200 9 (4.5) 3.79E-02 
KEGG Notch Signaling Pathway 47 6 (12.77) 3.82E-02 
KEGG Cell Adhesion Molecules (CAMs) 133 9 (6.77) 3.94E-02 
KEGG Hypertrophic Cardiomyopathy (HCM) 87 8 (9.2) 3.96E-02 
REA PI-3K Cascade 57 6 (10.53) 3.99E-02 
REA Platelet Aggregation (Plug Formation) 37 5 (13.51) 4.01E-02 
REA Signaling By EGFR 109 10 (9.17) 4.05E-02 
PID VEGFR1 Specific Signals 28 4 (14.29) 4.18E-02 
KEGG Leishmaniasis 72 6 (8.33) 4.48E-02 
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KEGG TGF-Beta Signaling Pathway 84 11 (13.1) 4.54E-02 
REA Phosphorylation Of CD3 And TCR Zeta 
Chains 
31 4 (12.9) 4.68E-02 
REA PD-1 Signaling 34 4 (11.77) 4.75E-02 
KEGG Autoimmune Thyroid Disease 52 4 (7.69) 4.93E-02 
KEGG Parkinson'S Disease 130 1 (0.77) 4.96E-02 
Abbreviation: PID, pathway interaction database. REA, Reactome. BIOC, Biocarta. aChronic myeloid 
leukemia often showed alterations in TP53, RB and p16/INK4A. bPDGF receptor signaling pathway. 
cReferring to signaling downstream of FGFR3, ERBB2 and E-cadherin. 
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Table 4-10. Pathways enriched with genes targeted by progression-associated miRNAs (miR-
16,/miR-378, miR-24 and miR-331-3p) in overall population 
Database Pathway 
All Genes 
in Pathway 
Target Genes 
in Pathway 
Empirical 
p value 
REA Neurotransmitter Receptor Binding And 
Downstream Transmission In The Postsynaptic 
Cell 
136 8 (5.88) 7.28E-03 
KEGG Purine Metabolism 161 7 (4.35) 9.44E-03 
REA Hemostasis 467 16 (3.43) 1.95E-02 
REA Nuclear Receptor Transcription Pathway 51 4 (7.84) 1.96E-02 
KEGG Long-Term Potentiation 70 5 (7.14) 2.01E-02 
REA Axon Guidance 266 12 (4.51) 2.17E-02 
PID Regulation Of CDC42 Activity 30 3 (10) 2.40E-02 
REA Transmission Across Chemical Synapses 190 8 (4.21) 3.04E-02 
REA DNA Repair 108 5 (4.63) 3.98E-02 
REA Glutamate Binding Activation Of AMPA 
Receptors And Synaptic Plasticity 
30 3 (10) 4.00E-02 
REA Trafficking Of AMPA Receptors 30 3 (10) 4.00E-02 
REA Membrane Trafficking 133 8 (6.02) 4.15E-02 
KEGG Olfactory Transduction 388 1 (0.26) 4.28E-02 
KEGG MAPK Signaling Pathway 272 11 (4.04) 4.31E-02 
KEGG Axon Guidance 129 6 (4.65) 4.40E-02 
REA Platelet Aggregation (Plug Formation) 37 3 (8.11) 4.50E-02 
PID Signaling Events Mediated By Focal Adhesion 
Kinase 
58 5 (8.62) 4.63E-02 
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Table 4-11. Pathways enriched with genes targeted by recurrence-associated miRNAs (miR-
146a and miR-152) in BCG-treated population 
Database Pathway 
All Genes 
in Pathway 
Target Genes 
in Pathway 
Empirical 
p value 
PID SHP2 Signaling 54 8 (14.82) 1.73E-04 
REA Interleukin-1 Signaling 40 7 (17.5) 1.81E-04 
REA TCR Signaling 69 10 (14.49) 1.94E-04 
REA Generation Of Second Messenger Molecules 42 5 (11.91) 3.33E-04 
PID Validated Targets Of c-Myc Transcriptional 
Repression 
63 9 (14.29) 4.89E-04 
REA Cyclin A CDK2-Associated Events At S Phase 
Entry 
66 7 (10.61) 5.32E-04 
PID FOXM1 Transcription Factor Network 41 8 (19.51) 5.78E-04 
PID TCR Signaling In Naive CD8+ T Cells 51 9 (17.65) 6.59E-04 
REA Cytokine Signaling In Immune System 220 16 (7.27) 1.16E-03 
PID TCR Signaling In Naive CD4+ T Cells 64 11 (17.19) 1.32E-03 
REA Signaling By Interleukins 106 10 (9.43) 2.62E-03 
KEGG Toll-Like Receptor Signaling Pathway 102 13 (12.75) 2.65E-03 
REA S Phase 112 8 (7.14) 2.97E-03 
KEGG Chemokine Signaling Pathway 189 13 (6.88) 3.01E-03 
KEGG Pathways In Cancer 325 24 (7.39) 4.24E-03 
REA Rig-I Mda5 Mediated Induction Of IFN-Alpha 
Beta Pathways 
76 7 (9.21) 4.44E-03 
PID ATF-2 Transcription Factor Network 58 8 (13.79) 5.14E-03 
KEGG Nod-Like Receptor Signaling Pathway 62 6 (9.68) 5.21E-03 
REA SCF(SKP2)-Mediated Degradation Of P27 P21 56 5 (8.93) 5.85E-03 
PID TRAIL Signaling Pathway 28 4 (14.29) 6.84E-03 
REA Nucleotide-Binding Domain Leucine Rich 
Repeat Containing Receptor (NLR) Signaling 
Pathways 
51 5 (9.8) 7.21E-03 
REA Cyclin E Associated Events During G1 S 
Transition 
65 6 (9.23) 7.36E-03 
KEGG Toxoplasmosis 132 9 (6.82) 7.39E-03 
REA NOD1 2 Signaling Pathway 31 4 (12.9) 7.41E-03 
REA Removal Of Licensing Factors From Origins 72 5 (6.94) 8.62E-03 
PID Aurora A Signaling 31 5 (16.13) 8.73E-03 
PID GMCSF-Mediated Signaling Events 36 6 (16.67) 9.74E-03 
PID Signaling Events Mediated By Stem Cell 
Factor Receptor (c-Kit) 
52 7 (16.67) 1.01E-02 
KEGG Intestinal Immune Network For IgA 
Production 
48 8 (16.67) 1.03E-02 
PID IL1-Mediated Signaling Events 35 9 (16.67) 1.06E-02 
REA Costimulation By The CD28 Family 77 10 (16.67) 1.19E-02 
KEGG Rig-I-Like Receptor Signaling Pathway 71 11 (16.67) 1.25E-02 
REA Peptide Ligand-Binding Receptors 186 12 (16.67) 1.32E-02 
REA Regulation Of DNA Replication 75 13 (16.67) 1.33E-02 
REA Interferon Gamma Signaling 73 14 (16.67) 1.45E-02 
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PID Wnt Signaling Network 28 15 (16.67) 1.61E-02 
REA G2 M Transition 84 16 (16.67) 1.71E-02 
KEGG Prostate Cancer 89 17 (16.67) 1.73E-02 
REA Downstream TCR Signaling 52 18 (16.67) 1.89E-02 
REA G1 S Transition 109 19 (16.67) 2.07E-02 
PID BCR Signaling Pathway 68 20 (16.67) 2.09E-02 
PID Internalization Of Erbb1 39 21 (16.67) 2.17E-02 
REA RNA Polymerase II Promoter Escape 39 22 (16.67) 2.20E-02 
REA RNA Polymerase II Transcription Pre-
Initiation And Promoter Opening 
39 23 (16.67) 2.20E-02 
REA RNA Polymerase II Transcription Initiation 
And Promoter Clearance 
39 24 (16.67) 2.20E-02 
REA RNA Polymerase II Transcription Initiation 39 25 (16.67) 2.20E-02 
REA HIV-1 Transcription Initiation 39 26 (16.67) 2.20E-02 
REA RNA Polymerase II HIV-1 Promoter Escape 39 27 (16.67) 2.20E-02 
KEGG Melanogenesis 101 28 (16.67) 2.31E-02 
PID ARF6 Trafficking Events 49 29 (16.67) 2.36E-02 
PID EGF Receptor (ERBB1) Signaling Pathway 32 30 (16.67) 2.38E-02 
REA Synthesis Of DNA 96 31 (16.67) 2.40E-02 
REA Gab1 Signalosome 39 32 (16.67) 2.53E-02 
PID P73 Transcription Factor Network 73 33 (16.67) 2.59E-02 
KEGG Small Cell Lung Cancer 84 34 (16.67) 2.61E-02 
BIOC Biocarta GSK3 Pathway 27 35 (16.67) 2.66E-02 
PID Integrins In Angiogenesis 74 36 (16.67) 2.72E-02 
KEGG Neurotrophin Signaling Pathway 127 37 (16.67) 2.73E-02 
PID Validated Transcriptional Targets Of Tap63 
Isoforms 
51 38 (16.67) 2.80E-02 
PID Signaling Events Mediated By Tcptp 41 39 (16.67) 2.80E-02 
REA Signal Transduction By L1 35 40 (16.67) 2.81E-02 
REA Interferon Signaling 110 41 (16.67) 2.87E-02 
REA Adaptive Immune System 482 42 (16.67) 2.88E-02 
PID Syndecan-1-Mediated Signaling Events 46 43 (16.67) 2.90E-02 
PID Fc-Epsilon Receptor I Signaling In Mast Cells 61 44 (16.67) 2.98E-02 
REA Signaling By EGFR 109 45 (16.67) 3.06E-02 
BIOC Biocarta IL1R Pathway 33 46 (16.67) 3.08E-02 
KEGG Inositol Phosphate Metabolism 57 47 (16.67) 3.12E-02 
REA IRS-Related Events 81 48 (16.67) 3.14E-02 
REA IRS-Mediated Signaling 81 49 (16.67) 3.14E-02 
BIOC Biocarta Toll Pathway 37 50 (16.67) 3.20E-02 
REA Orc1 Removal From Chromatin 70 51 (16.67) 3.27E-02 
REA Switching Of Origins To A Post-Replicative 
State 
70 52 (16.67) 3.27E-02 
KEGG Pancreatic Cancer 70 53 (16.67) 3.40E-02 
KEGG Insulin Signaling Pathway 137 54 (16.67) 3.60E-02 
KEGG Acute Myeloid Leukemia 57 55 (16.67) 3.63E-02 
REA GPCR Ligand Binding 410 56 (16.67) 3.71E-02 
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REA Insulin Receptor Signaling Cascade 86 57 (16.67) 3.77E-02 
REA L1CAM Interactions 94 58 (16.67) 3.83E-02 
PID Syndecan-4-Mediated Signaling Events 31 59 (16.67) 3.85E-02 
KEGG B Cell Receptor Signaling Pathway 75 60 (16.67) 3.87E-02 
KEGG ECM-Receptor Interaction 84 61 (16.67) 3.89E-02 
REA Mitotic G2-G2 M Phases 87 62 (16.67) 3.96E-02 
REA Signaling By PDGF 122 63 (16.67) 4.09E-02 
PID Integrin Family Cell Surface Interactions 26 64 (16.67) 4.10E-02 
REA Signaling By SCF-Kit 78 65 (16.67) 4.10E-02 
KEGG Basal Transcription Factors 35 66 (16.67) 4.11E-02 
PID Beta1 Integrin Cell Surface Interactions 65 67 (16.67) 4.24E-02 
REA Cell Cycle Mitotic 330 68 (16.67) 4.31E-02 
REA NCAM Signaling For Neurite Out-Growth 70 69 (16.67) 4.67E-02 
REA CD28 Co-Stimulation 31 70 (16.67) 4.83E-02 
KEGG Prion Diseases 36 71 (16.67) 4.93E-02 
PID Signaling Events Mediated By Ptp1B 52 72 (16.67) 4.96E-02 
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Table 4-12. Pathways enriched with genes targeted by progression-associated miRNAS (miR-
16, miR-21, miR-24 and miR-375) in BCG-treated population 
Database Pathway 
All Genes 
in Pathway 
Target Genes 
in Pathway 
Empirical 
p value 
BIOC Biocarta G1 Pathway 28 7 (25) 3.58E-04 
KEGG Cytokine-Cytokine Receptor Interaction 275 18 (6.545) 4.26E-04 
KEGG Allograft Rejection 37 4 (10.811) 1.68E-03 
KEGG P53 Signaling Pathway 68 8 (11.765) 1.87E-03 
KEGG MAPK Signaling Pathway 272 15 (5.515) 4.13E-03 
KEGG Primary Immunodeficiency 35 4 (11.429) 4.43E-03 
KEGG Glycerophospholipid Metabolism 79 5 (6.329) 4.81E-03 
PID P73 Transcription Factor Network 73 7 (9.589) 5.29E-03 
REA G0 And Early G1 25 5 (20) 5.39E-03 
PID FOXM1 Transcription Factor Network 41 8 (19.512) 5.52E-03 
KEGG Jak-Stat Signaling Pathway 155 9 (5.806) 6.36E-03 
REA Cell Cycle Mitotic 330 15 (4.545) 7.77E-03 
KEGG Malaria 51 5 (9.804) 1.01E-02 
REA Metabolism Of Vitamins and Cofactors 51 4 (7.843) 1.05E-02 
REA Metabolism Of Water-Soluble Vitamins and 
Cofactors 
51 4 (7.843) 1.05E-02 
PID Stabilization And Expansion Of The E-Cadherin 
Adherens Junction 
41 4 (9.756) 1.06E-02 
PID IL23-Mediated Signaling Events 37 4 (10.811) 1.22E-02 
BIOC Biocarta Inflam Pathway 29 4 (13.793) 1.25E-02 
REA E2F Mediated Regulation Of DNA Replication 33 5 (15.152) 1.44E-02 
KEGG Chagas Disease 104 7 (6.731) 1.45E-02 
REA Mitotic G1-G1 S Phases 135 10 (7.407) 1.66E-02 
PID Regulation Of Retinoblastoma Protein 64 6 (9.375) 1.90E-02 
KEGG Cell Cycle 124 8 (6.452) 2.18E-02 
KEGG Fructose And Mannose Metabolism 34 3 (8.824) 2.29E-02 
KEGG Glycolysis Gluconeogenesis 65 5 (7.692) 2.31E-02 
PID IL27-Mediated Signaling Events 26 4 (15.385) 2.38E-02 
PID c-myb Transcription Factor Network 81 6 (7.407) 2.45E-02 
PID E2F Transcription Factor Network 73 7 (9.589) 2.50E-02 
KEGG Olfactory Transduction 388 1 (0.258) 2.57E-02 
REA S Phase 112 7 (6.25) 2.71E-02 
PID ATF-2 Transcription Factor Network 58 5 (8.621) 2.75E-02 
REA G2 M Transition 84 5 (5.952) 2.77E-02 
KEGG Type I Diabetes Mellitus 43 4 (9.302) 2.83E-02 
KEGG Pathways In Cancer 325 13 (4) 2.91E-02 
KEGG Toxoplasmosis 132 7 (5.303) 3.00E-02 
REA Mitotic G2-G2 M Phases 87 5 (5.747) 3.03E-02 
KEGG Amino Sugar And Nucleotide Sugar Metabolism 47 4 (8.511) 3.06E-02 
REA Transmembrane Transport Of Small Molecules 427 2 (0.468) 3.17E-02 
KEGG Base Excision Repair 33 3 (9.091) 3.72E-02 
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PID Fc-Epsilon Receptor I Signaling In Mast Cells 61 4 (6.557) 4.01E-02 
KEGG Bladder Cancer 42 4 (9.524) 4.03E-02 
REA Lipid Digestion Mobilization And Transport 48 3 (6.25) 4.04E-02 
BIOC Biocarta NKT Pathway 28 3 (10.714) 4.10E-02 
KEGG DNA Replication 36 3 (8.333) 4.13E-02 
PID IL2 Signaling Events Mediated By Stat5 30 3 (10) 4.18E-02 
PID Calcineurin-Regulated NFAT-Dependent 
Transcription In Lymphocytes 
50 4 (8) 4.25E-02 
KEGG Galactose Metabolism 26 3 (11.538) 4.42E-02 
PID IL12-Mediated Signaling Events 65 5 (7.692) 4.49E-02 
REA G1 S Transition 109 7 (6.422) 4.96E-02 
REA Chromosome Maintenance 79 4 (5.063) 4.96E-02 
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4.4 Discussion 
The current study aimed to explore the potential of circulating miR in prediction of clinical 
outcomes in NMIBC. We found MRRS which improved traditional prediction model (EC) for overall 
recurrence (miR-24/miR-152), overall progression (miR-16/miR-378 and miR-24/miR-331-3p), BCG 
recurrence (miR-146a/miR-152) and BCG progression (miR-16/miR-21 and miR-24/miR-375). Among 
these MRRS, miR-16/miR-378 and miR-24/miR-331-3p alone performed as well as EC model in overall 
progression while miR-16/miR-21 and miR-24/miR-375 exceeded EC model in BCG progression. 
Finally, integration of miR-16/miR-21 and miR-24/miR-375 significantly improved EC model and 
resulted in 94.5% AUC.  
In a previous study, high miR-152 has been shown to be associated with lower recurrence-free 
survival (Jiang et al., 2015). And the anti-tumor activity of miR-152 has been attributed to induction of 
hypermethylation, inhibition of proliferation-associated molecules such as insulin-like growth factor 1 
receptor (IGF-1R), insulin receptor substrate 1 (IRS1), Krueppel-like factor 4  (KLF4), ADAM 
metallopeptidase domain 17 (ADAM17), fibroblast growth factor 2 (FGF2), CD151 (LIU et al., 2016). 
miR-24 has been demonstrated to induce apoptosis in bladder cancer cells by direct suppression of 
CARD recruited membrane associated protein 3  (CARMA3) (Zhang et al., 2015). Consistent with these 
reports, our results indicated that high miR-24/miR-152 ratio is associated with decreased risk of overall 
recurrence. In the overall progression panels, miR-16 was found to suppress proliferation in bladder 
cancer cell line, TCHu-1, via the inhibition of cyclin D1 (Jiang et al., 2013) while miR-378 was 
identified as an independent prognostic factor for both survival and recurrence (Homami and Ghazi, 
2016). The mechanism underlying miR-378 activity was suggested to be targeting RING-box protein 1 
(RBX1) (Ho et al., 2018, p. 1) and IFNγ receptor 1 (Ma et al., 2011). miR-331-3p was reported to exert 
anti-tumor activity by targeting Receptor tyrosine-protein kinase erbB-2 (ERBB2) (Epis et al., 2009), 
neuropilin 2 (NRP2) (Fujii et al., 2016, p. 2) and E2F1 (Guo et al., 2010). miR-146a was demonstrated 
to suppress migration and metastasis of bladder cancer cells via inhibition of Pituitary tumor-
transforming gene 1 (PTTG1) (Xiang et al., 2016, p. 1). miR-21 has been shown to overexpress in 
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bladder cancer (Drakaki et al., 2015), and leads to proliferation and chemoresistance (Tao et al., 2011). 
Finally, miR-375 was found downregulated in a wide variety of cancers including liver, gastric, 
esophagus, lung, head and neck (Yan et al., 2014).  
The enrichment of predicted target genes of these panel in certain pathways suggested possible 
mechanisms associated with recurrence and progression. Interestingly, if we compare enriched pathways 
in overall and BCG-treated groups, a lot more immune-related pathways were found in BCG-treated 
group. Since our blood samples were collected at diagnosis, none of the patients had received treatment. 
Therefore, the general immune function in patients might be a major factor which dominates the outcome 
of BCG treatment. And circulating miR might be a non-invasive surrogate for the general immune 
function. In addition, despite the well-known Warburg effect has been extensively studied in bladder 
cancer, the role of other metabolism pathways such as glycogen remained under-investigated (Lew et al., 
2015). Among the microRNA in our panels, miR-21 has been shown to modulate oxidative 
phosphorylation in pancreatic cells (Chen et al., 2018), miR-24 promotes metabolic reprogramming via 
targeting FIH-1, an inhibitor of hypoxic inducible factor α (HIFα) (Roscigno et al., 2017), and miR-375 
inhibits insulin secretion (El Ouaamari et al., 2008). And our results could provide preliminary hints for 
further study into the relationship between miR, metabolism and bladder cancer. 
 Normalization of circulating miR has been an issue of debate. Most early studies on miR 
expression were based on tissue samples where U6 and snoRNAs have been used as normalizer. 
However, these RNAs were either non-detectable or too variable to serve as reference (Wang et al., 
2012). To the best of knowledge, no single miR has been recognized to be a stable internal reference. 
Proposed strategies for normalization in previous studies included the use of a global expression 
parameter such as mean expression per sample (Mestdagh et al., 2009), identification of stable miRs in 
the dataset of interest using rank-invariant method (Pelz et al., 2008), and miR ratios (Boeri et al., 2011). 
We chose miR ratios because our approach is not a global profiling of all miR. In addition, the use of 
global expression parameter removed the global difference between samples while the variation between 
samples might be relevant in pathophysiology. And identifying stable miRs requires screening a large 
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number of miRs among multiple samples to identify invariant reference miRs. Thus, we decided that the 
third approach (miR ratios) was the most suitable strategy. Choosing stable and biologically relevant 
miR maximized the chance of finding biomarkers associated with clinical outcomes and provided results 
that were easier to interpret.  
 The strength of our study included the selecting both stably expressed and tumor related miR to 
optimize the change of finding relevant biomarkers. And we overcame the major caveat of using miR 
ratios, multiple comparison, by implementing a discovery-validation phase design. We also provided a 
more comprehensive view by investigating MRRS alone or integrating them into traditional EC model. 
Limitations of the current study included the lack of validation from an independent cohort, samples 
focused on ethnically Caucasian and limited number of technical replicates. Without external validation 
and being ethnically uniform limits the generalizability of our findings. And running duplicate technical 
repeats lowered the detection rate. 
 In conclusion, we have discovered and internally validated MRRS that were associated with 
clinical outcomes in NMIBC. And the MRRS for progression in overall and BCG-treated patients could 
be utilized alone or integrated into EC model while the MRRS for recurrence improved EC model 
prediction. Our results also suggested that immune- and metabolism-related pathways might be 
associated with clinical outcomes of NMIBC. 
  
120 
 
5. Conclusions and Future Directions 
This dissertation described several different aspects of molecular epidemiology of two common 
cancer types. Chapter 2 and 3 started with genome and transcriptome scale screening, which presents an 
overall picture of molecular differences between various pathological lesions. Results obtained from 
these studies provided basic understanding of particular types of lesions and served as a source for 
hypotheses generation. Chapter 2 and 3 of this dissertation served as an early step towards a more 
comprehensive premalignant genome atlas (PGA). Chapter 4 focused on strategies which quickly narrow 
down results from high-throughput screening and validation of these candidates in a larger cohort. 
Chapter 2 and 3 aimed at deciphering the physiology of cancers while Chapter 4 produced a biomarker 
panel that is clinically-oriented. 
In Chapter 2, we performed whole exome sequencing on conventional adenoma (CNAD) and 
sessile serrated adenoma (SSA) to build an atlas of somatic mutations for both subtypes. Consistent with 
previous models, at least 50% of the SSA carried missense BRAF mutations. Unfortunately, we weren’t 
able to validate whether all the SSA were CIMP-high and CIMP-low regardless of BRAF mutation 
status as mentioned in the review of Jass in 2007 (Jass, 2007). However, our finding identified a 
potential driver (KRTAP4-5) which might be exclusive for CNAD and SSA. Some of the profiles also 
cast doubt on whether SSA is a major source for hypermutated colorectal cancer (CRC) due to the 
absence of APC mutations. Further studies will be required to determine whether the critical step of SSA 
tumorigenesis is dependent on APC mutation. In chapter 3, we used transcriptome sequencing to locate 
DEGs among advanced adenoma (ADV), non-advanced adenoma (NAD), CNAD, SSA and CRC. And 
many pathways enriched with these DEGs warrants further investigation to characterize the biological 
basis for CRC development. 
Combining novel algorithms commonly used in the machine learning field, random forest, we were 
able to prioritize and discover the most efficient 20-gene panel which separates CNAD and CRC with 
high specificity and sensitivity. This model remained to be validated in a larger cohort. Yet, the success 
in applying random forest in classification of mutational profiles suggested that the field of molecular 
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epidemiology could benefit significantly from the computer science field. Recent advances in artificial 
intelligence demonstrated the power of neural network (NN). However, unlike random forest which 
illustrates which feature is important for classification, NN is still a black box which merely provides 
output without information on the process. Therefore, for fields like biomedical sciences, random forest 
may be a better option because the important feature used for classification often reflects underlying 
mechanisms. . In our studies this holds true judging by serves better judging by the fact that the 20-gene 
panel we discovered contained many known tumor driver genes, and the fact that expression of these 
genes turned out to be a good classifier at the transcriptome level as well. These genes are very likely to 
participate in the essential functions of premalignant lesion pathophysiology and drive CRC 
development. 
The cancer genome atlas (TCGA) revolutionized the biomedical field by generating vast amounts of 
data for multiple biological aspects including genome, transcriptome, methylome, microRNAome, and 
proteome. Various software packages were developed to analyze these data and provided unparalleled 
insights into cancer biology which ultimately facilitate the progress of precision medicine. Nonetheless, 
a similar approach have been suggested for premalignant lesions to further our understanding of the 
tumorigenesis process and hopefully lead to novel early detection and preventive interventions. Despite 
the framework of multi-omics have been largely laid out in TCGA, the premalignant genome atlas 
(PGA) still faces technical difficulties. One such difficulty is that premalignant lesions are usually small 
in size (less than 1cm in diameter), and extracting enough DNA, RNA, or protein from the same piece of 
tissue is a challenge. But these technical hurdles have been gradually overcome because of the advances 
in technology. For example, whole exome sequencing studies used to require 3 µg or more DNA for 
library preparation. But recent technologies have provided two solutions: whole genome amplification 
and preparation of libraries from less than 100 ng DNA. Although these solutions do benefit studying 
low amount of DNA, amplification of whole genome have been shown to introduce bias, and certain 
studies like detection of circulating tumor DNA required the ability to analyze less than 20 ng of DNA. 
We are rapidly reaching the point where large scale PGA may become feasible. Furthermore, in addition 
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to the -omics profiles provided in TCGA, there were other newer -omics profiling approaches that could 
be incorporated. Two of such -omics are microbiome and metabolome.  
Many microorganisms including bacteria, fungi and viruses have been associated with cancer risk. 
The mechanisms of carcinogenesis include inflammation, immune suppression, growth signals, and 
introduction of mutations (Goodman and Gardner, 2018), and many microorganisms are capable of more 
than one. One famous example is Helicobacter pylori which promotes gastric epithelium growth, 
induces inflammation, and reduce apoptosis at the same time (Peek and Blaser, 2002). A study by de 
Martel et al. estimated that 3.3-32.7% of newly diagnosed cancers could be attributed to infectious 
agents (de Martel et al., 2012). Therefore, a more comprehensive collection of microbiome in both 
malignant and premalignant lesions could lead to novel discoveries on the involvement of 
microorganisms.  
Metabolome quantifies metabolites in a high-throughput manner, and metabolites are direct 
indicators for cellular enzymes. Alteration of metabolites have been discovered in multiple cancers 
including lung, breast, colorectal, pancreatic, and leukemia (Snyder et al., 2015). In lung cancer, 
metabolomics study revealed that cancer tissues had higher production of glutamate and aspartate 
suggesting activation of glycolysis, pyruvate carboxylation, and Krebs cycle (Fan et al., 2009). Since 
metabolism reprogramming has been considered a hallmark of cancer, metabolome will serve as an 
instrumental screening for dysregulated metabolic pathways and guide targeted therapy in cancer. And 
the metabolome in PGA will help elucidate the roles of metabolism alteration in tumorigenesis. 
Chapter 4 investigated the potential of using serum microRNA as a biomarker to predict the risk of 
recurrence and progression for NMIBC. We found that the microRNA panel which predicts progression 
of BCG-treated NMIBC was associated with immune function, implicating that immune signatures will 
dictate the outcome of immune therapy. Indeed, a series of studies have started to identify immune 
signatures which are capable of predicting treatment success as summarized by Gnjatic et al. (Gnjatic et 
al., 2017). These studies included biomarkers from both the cancer site and blood. The serological 
biomarkers included immune cell composition, cytokines, complements, and T cell receptor diversity. 
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Previous studies have demonstrated that microRNA is as an instrumental component in immune 
regulation (Gracias and Katsikis, 2011). Therefore, serum microRNA have a strong potential to be a 
clinically relevant biomarker, and our results supported this point. 
Limitations of the current study lies in a couple aspects. First, the technical challenge of extracting 
sufficient materials for -omics analysis from small pieces of tissue, such as the case with premalignant 
lesions, has not been completely solved. Thus, we were unable to perform exome and transcriptome 
sequencing in the same patient when we first carried out studies in Chapter 2. However, we have 
experimented and adapted novel technologies to extract both DNA and RNA for samples in Chapter 3. A 
future project to analyze the DNA of these samples will be a better source for integrated analysis on both 
exome and transcriptome level. Second, we were unable to perform microbiome, proteome, and 
metabolome studies in the same sample due to limitations in resources. Future projects covering these 
aspects will make the PGA project truly shine. Third, sample size has always been a sensitive issue in 
epidemiological studies because this is one of the best ways to control for confounding factors. Our 
sample size in colorectal adenomas did not allow us to adjust for the differences in age, race, and other 
life-style factors. From an epidemiological point of view, inclusion of these factors will help us better 
characterize confounders and have a better chance to find true biological targets rather than surrogates. 
Increasing sample size along with more detailed data collection such as food frequency questionnaire 
will be the major consideration for future studies. Fourth, some studies have raised concerns about serum 
microRNA results being un-reproducible. Possible explanations included sample quality, sample size, 
differences between individuals, unreliable normalizers, and environmental factors which might 
confound serum microRNA profiles (Singh et al., 2016). To remedy some of these pitfalls, we performed 
quality control to make sure no significant signs of hemolysis was present. And we designed our study 
with a larger sample size as well as controlled for usual demographic factors and disease diagnosis. We 
also employed a discovery and validation phase design to prevent possible false positives which plaques 
many high-throughput screening. Despite our efforts, the current design is cross-sectional and might not 
be able to capture a biomarker if the true signal lies in the dynamics of biomarkers. For instance, glucose 
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tolerance test is a better indicator for diabetes than fasting glucose. It wouldn’t be a surprise if the 
difference between pre- and post-treatment microRNA serves as a better biomarker. A future study with 
another cohort to validate our findings and a novel design measuring both pre- and post-treatment 
microRNA might be warranted. 
 In conclusion, the results reported in this dissertation is a start for building a more 
comprehensive PGA for the colorectal adenomas, which will not only decode the tumorigenesis in 
colorectal adenomas but will also ultimately lead to precision prevention just like TCGA helped improve 
precision medicine. The discovery and validation of serum microRNA associated with clinical outcomes 
of NMIBC took us one step further from understanding the difference between cancers to designing 
biomarker tests applicable in a clinical setting. These two approaches taken together demonstrated how 
recent advances in molecular biology shape the changing face of epidemiology.   
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